Document:

EX-4.8

 Exhibit 4.8 

HTG MOLECULAR DIAGNOSTICS, INC. 

AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTOR RIGHTS
AGREEMENT (this “Agreement”) is entered into as of December 22, 2014, by and among HTG MOLECULAR DIAGNOSTICS, INC., a Delaware
corporation (the “Company”), certain holders of common stock, $0.001 par value per share, of the Company (“Common Stock”) listed on Exhibit A-1 hereto (the “Common
Stockholders”) and the holders of Preferred Stock (as defined below) listed on Exhibit A-2 hereto (the “Investors”). The Common Stockholders and the Investors may be referred to herein individually as a
“Stockholder” and collectively as “Stockholders.” 
 RECITALS 

WHEREAS, in connection with the Company’s prior sale of its Series E Convertible Preferred Stock,
the Company and the Stockholders entered into that certain Amended and Restated Investor Rights Agreement dated as of February 4, 2014 (the “Prior Agreement”); and 

WHEREAS, in anticipation of the consummation of the Initial Offering (as defined below), the Company and
the undersigned Stockholders (on behalf of themselves and all other Investors and all Common Stockholders) desire to enter into this Agreement in order to amend and restate the Prior Agreement as set forth herein. 

AGREEMENT 

NOW, THEREFORE, in consideration of the premises and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 SECTION 1. GENERAL. 

1.1 Amendment and Restatement of Prior Agreement. The Prior Agreement is hereby amended and restated in its entirety as set forth
herein, contingent and effective upon the closing of the Initial Offering (the “Effective Time”), and all rights and covenants made under the Prior Agreement (including registration rights and related notice provisions),
contingent and effective upon the Effective Time, are hereby terminated in their entirety and shall have no further force or effect whatsoever; provided, however, that, if the Initial Offering is not completed for any reason by March 31,
2015 (or such later date as consented to by the Requisite Investors (as such term is defined in the Prior Agreement)), or upon the earlier abandonment of the Initial Offering (whether as a result of the determination of the Board of Directors not to
file with the Commission a registration statement for the Initial Offering or the withdrawal by the Company of the registration statement with respect thereto), this Agreement shall be null and void and the Prior Agreement shall remain in full force
and effect. Notwithstanding the foregoing, the obligations, if any, of Novo, Fletcher and MCV (each as defined in the Prior Agreement) in the intention letters dated on or about June 9, 2011 shall remain discharged in full, effective as of
November 2, 2012. 
 1.2 Definitions. As used in this Agreement, the following terms shall have the following respective
meanings: 
 “Affiliate” has the meaning ascribed to that term in Rule 12b-2 under the Exchange Act, or any
successor rule. 
 “Certificate of Incorporation” means the Company’s Amended and Restated Certificate of
Incorporation filed with the Secretary of State of the State of Delaware on February 3, 2014, as amended and/or restated from time to time. 

“Commission” means the Securities and Exchange Commission and any successor agency of the federal government
administering the Securities Act and the Exchange Act. 
 “Exchange Act” means the Securities Exchange Act of 1934,
as amended, and any similar or successor federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect from time to time. 

“Initial Offering” means the Company’s first firm commitment underwritten public offering of its Common Stock
registered under the Securities Act, in connection with which the outstanding shares of Preferred Stock are converted into shares of Common Stock. 

  
 1 

 “Person” or “person” means an individual,
corporation, partnership, limited liability company, joint venture, trust or unincorporated organization, or a government or any agency or political subdivision thereof. 

“Preferred Stock” means the Company’s Series A Convertible Preferred Stock, Series B Convertible Preferred
Stock, Series C-1 Convertible Preferred Stock, Series C-2 Convertible Preferred Stock, Series D Convertible Preferred Stock and Series E Convertible Preferred Stock held by the Stockholders. 

The terms “register,” “registered” and “registration” refer to a
registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the declaration or ordering of the effectiveness of such registration statement, or, as
the context may require, under the Exchange Act or applicable state securities laws. 
 “Registrable Securities”
means (i) shares of Common Stock issued upon the conversion of the Preferred Stock, (ii) for purposes of Sections 2.1, 2.2, 2.4, 2.6, 2.7, 2.8, 2.9, 2.14 and 2.15 only, shares of Common Stock held by the Common Stockholders as of the date
hereof, and (iii) any shares of Common Stock issued or issuable with respect to any of the foregoing upon any stock split, stock dividend, recapitalization, reorganization, merger, consolidation, sale of assets or similar event, excluding, in
any event, securities that (a) have been registered under the Securities Act pursuant to an effective registration statement filed thereunder and disposed of in accordance with such registration statement, (b) have been sold pursuant to
Rule 144, (c) are eligible for sale without volume restrictions pursuant to Rule 144 or (d) sold in a private transaction in which the transferor’s rights under Section 2 of this Agreement are not assigned. 

“Requisite Investors” means the holders of at least 60% of the then-outstanding Registrable Securities that were
issued upon conversion of the Series E Convertible Preferred Stock of the Company. 
 “Rule 144” means Rule 144 as
promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

“Securities Act” means the Securities Act of 1933, as amended, and any successor federal statute, and the rules and
regulations of the Commission thereunder, all as the same shall be in effect from time to time. 
 SECTION 2. TRANSFER OF REGISTRABLE SECURITIES;
REGISTRATION RIGHTS.  
 2.1 Restrictive Legend. Each certificate or uncertificated share representing Registrable
Securities shall, except as otherwise provided in this Section 2, be stamped or otherwise imprinted or notated, as applicable, with a legend substantially in the following form (in addition to any legend required under applicable state
securities laws): 
 “THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR
ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT COVERING SUCH SECURITIES UNDER THE SECURITIES ACT OF 1933
AND ANY APPLICABLE STATE SECURITIES LAWS, OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS THEREOF.” 
 Upon request
of a holder of such Registrable Securities, the Company shall remove the foregoing legend from the certificate or uncertificated shares or issue to such holder a new certificate or uncertificated shares therefor free of such legend if there is an
effective registration statement covering the securities represented by such certificate or uncertificated shares or, with such request, the Company shall have received either the opinion of counsel or no-action letter referred to in
Section 2.2 (unless such opinion of counsel or no-action letter is not required by Section 2.2), subject in each case to the continued effectiveness of such registration statement, opinion of counsel or no-action letter. 

2.2 Notice of Proposed Transfer. Prior to any proposed sale, pledge, hypothecation or other transfer of any Registrable Securities
(other than under the circumstances described in Section 2.3, 2.4 or 2.5), the holder thereof shall give written notice to the Company of its intention to effect such sale, pledge, hypothecation or other transfer. Each such notice shall
describe the manner of the proposed sale, pledge, hypothecation or other transfer and, if requested by the Company, shall be accompanied by either (i) an opinion of counsel reasonably satisfactory to the Company to the effect that the proposed
sale, pledge, hypothecation or other transfer may be effected without registration under the Securities Act or (ii) a “no-action” letter from the Commission to the effect that the distribution

  
 2 

 
of such securities without registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto (it being understood that if such transfer, in
the reasonable opinion of the Company upon advice of its counsel, will be in accordance with Rule 144, the Company shall not require an opinion of counsel or no-action letter), whereupon the holder of such securities shall be entitled to transfer
such securities in accordance with the terms of its notice; provided, however, that no such opinion of counsel or no-action letter shall be required for a distribution to one or more partners of the transferor (in the case of a
transferor that is a partnership) or to a stockholder (in the case of a transferor that is a corporation) in each case in respect of the beneficial interest of such partner or stockholder. All certificates or uncertificated shares, as applicable,
for Registrable Securities transferred as provided above shall bear the appropriate restrictive legend set forth in Section 2.1, except that such certificate or uncertificated shares shall not bear such legend if (a) such transfer is in
accordance with the provisions of Rule 144 (or any other rule permitting public sale without registration under the Securities Act) or (b) the opinion of counsel or “no-action” letter referred to above is to the further effect that
the transferee and any subsequent transferee (other than an affiliate of the Company) would be entitled to transfer such securities in a public sale without registration under the Securities Act or that such legend is not required to establish
compliance with any provisions of the Securities Act. Notwithstanding any other provision hereof, the restrictions provided for in this Section 2.2 shall not apply to securities which are not required to bear the legend prescribed by
Section 2.1 in accordance with the provisions of that Section. 
 2.3 Required Registration. 

(a) At any time after the date that is 180 days following the date of the underwriting agreement for the Initial Offering,
holders of at least fifty percent (50%) of the total shares of Registrable Securities then outstanding may request that the Company register under the Securities Act all or any portion of the shares of Registrable Securities held by such
requesting holder or holders for sale in the manner specified in such notice, provided that the reasonably anticipated price to the public of such shares would be at least $7,500,000 (before deducting any Selling Expenses (as defined in
Section 2.7)). 
 (b) Following receipt of any notice under Section 2.3(a), the Company shall immediately notify
all holders of Registrable Securities from whom notice has not been received and such holders shall then be entitled within thirty (30) days after receipt of such notice from the Company to request the Company to include in the requested
registration all or any portion of their shares of Registrable Securities, subject to the limitations set forth in this Section 2.3(c). The Company shall use its best efforts to register under the Securities Act, for public sale in accordance
with the method of disposition specified in the notice from requesting holders described in paragraph (a) above, the number of shares of Registrable Securities specified in such notice (and in all notices received by the Company from other
holders within thirty (30) days after the receipt of such notice by such holders, subject to the limitations set forth in Section 2.3(c)). The Company shall be obligated to register Registrable Securities pursuant to this
Section 2.3 on two (2) occasions only; provided, however, that such obligation shall be deemed satisfied only when a registration statement covering all of the shares of Registrable Securities requested to be included in
such registration by the holders of Registrable Securities in accordance with the method of disposition specified by the requesting holders shall have become effective and, if such method of disposition is a firm commitment underwritten public
offering, all such shares shall have been sold pursuant thereto. Notwithstanding anything to the contrary contained herein, no request may be made under this Section 2.3 after the effective date of a registration statement filed by the Company
covering a firm commitment underwritten public offering and prior to ninety (90) days after the effective date of such registration statement. 

(c) If the holders requesting such registration intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 2.3 and the Company shall include such information in the written notice referred to in paragraph (b) above. The right of
any holder to registration pursuant to this Section 2.3 shall be conditioned upon such holder’s agreeing to participate in such underwriting and to permit inclusion of such holder’s Registrable Securities in the underwriting. If such
method of disposition is an underwritten public offering, the Company shall designate the managing underwriter of such offering, which underwriter shall be reasonably acceptable to the holders of at least a majority in interest of the shares of
Registrable Securities to be sold in such offering. A holder may elect to include in such underwriting all or a part of the Registrable Securities it holds, subject to the limitations required by the managing underwriter as provided for in
Section 2.3(d) below. 
 (d) A registration statement filed pursuant to this Section 2.3 may, subject to the
following provisions, include (i) shares of Common Stock for sale by the Company for its own account and (ii) shares of Common Stock held by persons who by virtue of agreements with the Company in compliance with the provisions of
Section 2.13 hereof are entitled to include such shares in such registration (the “Other Stockholders”), in each case for sale in accordance with the method of disposition specified by the requesting holders. If such
registration shall be underwritten, the Company and Other Stockholders proposing to distribute their shares through such underwriting shall enter into an underwriting agreement in customary form with the representative of the underwriter or

  
 3 

 
underwriters selected for such underwriting on terms no less favorable to the Company and such Other Stockholders than the terms afforded the holders of Registrable Securities. If and to the
extent that the managing underwriter determines that marketing factors require a limitation on the number of shares to be included in such registration, then the shares of Common Stock held by Other Stockholders (other than Registrable Securities)
and shares of Common Stock to be sold by the Company for its own account shall be excluded from such registration to the extent so required by such managing underwriter, and unless the holders of such shares and the Company have otherwise agreed in
writing, such exclusion shall be applied first to the shares held by the Other Stockholders to the extent required by the managing underwriter, then to the shares of Common Stock of the Company to be included for its own account to the extent
required by the managing underwriter. If the managing underwriter determines that marketing factors require a further limitation of the number of Registrable Securities to be registered under this Section 2.3, then Registrable Securities shall
be excluded in such manner that the securities to be sold shall be allocated among the selling holders pro rata based on their ownership of Registrable Securities; provided however that all Registrable Securities that were originally issued as
Common Stock shall be excluded before excluding any Registrable Securities that were originally issued as Preferred Stock. In any event all securities to be sold other than Registrable Securities will be excluded prior to any exclusion of
Registrable Securities. No Registrable Securities or any other security excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included in such registration. If any holder of Registrable Securities or Other
Stockholder who has requested inclusion in such registration as provided above disapproves of the terms of the underwriting, such holder of securities may elect to withdraw therefrom by written notice to the Company and the managing underwriter. The
securities so withdrawn shall also be withdrawn from registration. Except for registration statements on Form S-4, S-8 or any comparable forms or successors thereto or another form not available for registering the Registrable Securities for sale to
the public, the Company will not file with the Commission any other registration statement with respect to its Common Stock, whether for its own account or that of other stockholders, from the date of receipt of a notice from requesting holders
pursuant to this Section 2.3 until one hundred eighty (180) days after the effective date of such registration, subject to the terms and conditions of this Agreement. 

(e) If at the time of any request to register Registrable Securities pursuant to this Section 2.3, the Company is engaged
in any activity which, in the good faith determination of the Board of Directors, would be adversely affected by the requested registration to the material detriment of the Company, then the Company may, at its option, direct that such request be
delayed for a period not to exceed ninety (90) days from the date of a request for registration, such right to delay a request to be exercised by the Company not more than once in any one (1)-year period.

 2.4 Incidental Registration. If the Company at any time proposes to register any of its securities under the Securities Act for
sale to the public, whether for its own account or for the account of other security holders or both (except with respect to registration statements on Forms S-4, S-8 or any comparable forms or successors thereto or another form not available for
registering the Registrable Securities for sale to the public), each such time it will promptly give written notice to all holders of the Registrable Securities of its intention so to do. Upon the written request of any such holder received by the
Company within twenty (20) days after the giving of any such notice by the Company to register any or all of its Registrable Securities, the Company will use its best efforts to cause the Registrable Securities as to which registration shall have
been so requested to be included in the securities to be covered by the registration statement proposed to be filed by the Company, all to the extent required to permit the sale or other disposition by the holder (in accordance with its written
request) of such Registrable Securities so registered. If the registration of which the Company gives notice is for a registered public offering involving an underwriting, the Company shall so advise the holders of Registrable Securities as a part
of the written notice given pursuant to this Section 2.4. In such event the right of any holder of Registrable Securities to registration pursuant to this Section 2.4 shall be conditioned upon such holder’s participation in such underwriting to
the extent provided herein. All holders of Registrable Securities proposing to distribute their securities through such underwriting shall (together with the Company and the Other Stockholders distributing their securities through such underwriting)
enter into an underwriting agreement in customary form with the underwriter or underwriters selected for underwriting by the Company. Notwithstanding any other provision of this Section 2.4, if the underwriter determines that marketing factors
require a limitation on the number of shares to be underwritten, such limitation will be imposed pro rata with respect to all securities whose holders have a contractual, incidental (“piggyback”) right to include such securities in the
registration statement and as to which inclusion has been requested pursuant to such right; provided, however, that the number of Registrable Securities shall not be reduced below thirty percent (30%) of the number of Registrable
Securities requested to be included in such underwriting; and provided further that the number of Registrable Securities underlying Preferred Stock shall not be reduced below twenty-five percent (25%) of the number of securities
included in such underwriting. Notwithstanding the foregoing provisions, the Company may withdraw any registration statement referred to in this Section 2.4 for any reason without thereby incurring any liability to the holders of Registrable
Securities. If any holder of Registrable Securities disapproves of the terms of any such underwriting, it may elect to withdraw therefrom by written notice to the Company and the underwriter. Any Registrable Securities or other securities excluded
or withdrawn from such underwriting shall be withdrawn from such registration. 

  
 4 

 2.5 Registration on Form S-3. 

(a) In addition to the rights provided in Sections 2.3 and 2.4, if at any time (i) one or more holders of Registrable
Securities constituting at least fifty percent (50%) of the total shares of Registrable Securities then outstanding requests that the Company file a registration statement on Form S-3 or any comparable or successor form thereto for a public
offering of all or any portion of the shares of Registrable Securities held by such requesting holder or holders, the reasonably anticipated aggregate price to the public of which would be at least $5,000,000 (before deducting any Selling Expenses),
and (ii) the Company is a registrant entitled to use Form S-3 or any comparable or successor form thereto to register such shares, then the Company shall use its best efforts to register under the Securities Act on Form S-3 or any comparable or
successor form thereto, for public sale in accordance with the method of disposition specified in such notice, the number of shares of Registrable Securities specified in such notice. Whenever the Company is required by this Section 2.5 to use
its best efforts to effect the registration of Registrable Securities, each of the procedures and requirements of Section 2.3, including, but not limited to, the cut-back provisions and the requirement that the Company notify all holders of
Registrable Securities from whom notice has not been received and provide them with the opportunity to participate in the offering, shall apply to such registration; provided, however, that the number of registrations on Form S-3 which
may be requested and obtained under this Section 2.5 during any twelve (12)-month period shall not exceed two (2). 

(b) The Company shall use its commercially reasonable efforts to qualify for registration on Form S-3 or any comparable or
successor form or forms; and to that end the Company shall use its commercially reasonable efforts to register (whether or not required by law to do so) the Common Stock under the Exchange Act in accordance with the provisions of the Exchange Act
following the effective date of the first registration of any securities of the Company on Form S-1 or any comparable or successor form. 

(c) If at the time of any request to register Registrable Securities pursuant to this Section 2.5, the Company is engaged
in any activity which, in the good faith determination of the Board of Directors, would be adversely affected by the requested registration to the material detriment of the Company, then the Company may at its option direct that such request be
delayed for a period not to exceed ninety (90) days from the date of a request for registration, such right to delay a request to be exercised by the Company not more than once in any one (1)-year period.

 2.6 Registration Procedures. If and whenever the Company is required by the provisions of Section 2.3, 2.4 or 2.5 to use its
best efforts to effect the registration of any Registrable Securities under the Securities Act, the Company will, as expeditiously as possible: 

(a) prepare and file with the Commission a registration statement (which, in the case of an underwritten public offering
pursuant to Section 2.3, shall be on Form S-1 or other form of general applicability satisfactory to the managing underwriter selected as therein provided) with respect to such securities including executing an undertaking to file
post-effective amendments and use its best efforts to cause such registration statement to become and remain effective for the period of the distribution contemplated thereby; 

(b) prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus
used in connection therewith as may be necessary to keep such registration statement effective for the period specified herein and comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities covered
by such registration statement in accordance with the sellers’ intended method of disposition set forth in such registration statement for such period; 

(c) furnish to each seller of Registrable Securities and to each underwriter such number of copies of the registration
statement and each such amendment and supplement thereto (in each case including all exhibits) and the prospectus included therein (including each preliminary prospectus) as such persons reasonably may request in order to facilitate the public sale
or other disposition of the Registrable Securities covered by such registration statement; 
 (d) use its best efforts to
register or qualify the Registrable Securities covered by such registration statement under the securities or “blue sky” laws of such jurisdictions as the sellers of Registrable Securities or, in the case of an underwritten public
offering, the managing underwriter reasonably shall request; 
 (e) use its best efforts to list the Registrable Securities
covered by such registration statement with any securities exchange or quotation system on which the Common Stock of the Company is then listed; 

  
 5 

 (f) comply with all applicable rules and regulations under the Securities Act and
Exchange Act; 
 (g) immediately notify each seller of Registrable Securities and each underwriter under such registration
statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event of which the Company has knowledge as a result of which the prospectus contained in such registration
statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing, and
promptly prepare and furnish to such seller a reasonable number of copies of a prospectus supplement or amendment so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not include an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; 

(h) if the offering is underwritten and at the request of any seller of Registrable Securities, furnish on the date that
Registrable Securities are delivered to the underwriters for sale pursuant to such registration: (i) an opinion of counsel representing the Company for the purposes of such registration, dated such date, addressed to the underwriters to such
effects as reasonably may be requested by counsel for the underwriters, and executed counterparts of such opinion addressed to the sellers of Registrable Securities to the same effects as requested by counsel for the underwriters, and (ii) a
letter, dated such date, from the independent public accountants retained by the Company, addressed to the underwriters stating that they are independent public accountants within the meaning of the Securities Act and that, in the opinion of such
accountants, the financial statements of the Company included in the registration statement or the prospectus, or any amendment or supplement thereof, comply as to form in all material respects with the applicable accounting requirements of the
Securities Act, and such letter shall additionally cover such other financial matters with respect to such registration as such underwriters reasonably may request; 

(i) make available for inspection by each seller of Registrable Securities, any underwriter participating in any distribution
pursuant to such registration statement and any attorney, accountant or other agent retained by such seller or underwriter, reasonable access to all financial and other records, pertinent corporate documents and properties of the Company, as such
parties may reasonably request, and cause the Company’s officers, directors and employees to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent in connection with such registration
statement; 
 (j) cooperate with the selling holders of Registrable Securities and the managing underwriter, if any, to
facilitate the timely preparation and delivery of certificates or uncertificated shares representing Registrable Securities to be sold, such certificates or uncertificated shares to be in such denominations and registered in such names as such
holders or the managing underwriter may request at least two (2) business days prior to any sale of Registrable Securities; and 

(k) permit any holder of Registrable Securities which holder, in the sole and exclusive judgment, exercised in good faith, of
such holder, might be deemed to be a controlling person of the Company, to participate in good faith in the preparation of such registration or comparable statement and to require the insertion therein of material, furnished to the Company in
writing, which in the reasonable judgment of such holder and its counsel should be included. 
 For purposes of this
Agreement, the period of distribution of Registrable Securities in a firm commitment underwritten public offering shall be deemed to extend until each underwriter has completed the distribution of all securities purchased by it, and the period of
distribution of Registrable Securities in any other registration shall be deemed to extend until the earlier of the sale of all Registrable Securities covered thereby or one hundred eighty (180) days after the effective date thereof,
provided, however, in the case of any registration of Registrable Securities on Form S-3 or a comparable or successor form which are intended to be offered on a continuous or delayed basis, such
one hundred eighty (180)-day period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule
under the Securities Act, permits an offering on a continuous or delayed basis, and provided further that applicable rules under the Securities Act governing the obligation to file a post-effective amendment, permit, in lieu of filing a
post-effective amendment which (y) includes any prospectus required by Section 10(a)(3) of the Securities Act or (z) reflects facts or events representing a material or fundamental change in the information set forth in the
registration statement, the incorporation by reference of information required to be included in clauses (y) and (z) above contained in periodic reports filed pursuant to Section 13 or 15(d) of the Exchange Act in the registration
statement. 
 In connection with each registration hereunder, the sellers of Registrable Securities will furnish to the
Company in writing such information requested by the Company and the managing underwriter, if any, with respect to themselves and the proposed distribution by them as shall be reasonably necessary in order to assure compliance with Federal and
applicable state securities laws. Any holder of 

  
 6 

 
Registrable Securities may withdraw all or part of its Registrable Securities from a registration pursuant to Section 2.3, 2.4 or 2.5 at any time prior to the effective date of such
registration. 
 2.7 Expenses. 

(a) All expenses incurred by the Company in complying with Sections 2.3, 2.4 and 2.5, including, without limitation, all
registration and filing fees, printing expenses, fees and disbursements of counsel and independent public accountants for the Company, fees and expenses (including counsel fees) incurred in connection with complying with state securities or
“blue sky” laws, fees of the Financial Industry Regulatory Authority (FINRA), transfer taxes, fees of transfer agents and registrars, costs of any insurance which might be obtained by the Company with respect to the offering by the
Company, and reasonable fees and disbursements of one counsel selected by at least a majority in interest of the sellers of Registrable Securities (which fees and disbursements of counsel shall not exceed $25,000 per required registration or S-3
registration and shall not exceed an aggregate of $50,000 for all registrations effected during any twelve (12)-month period), but excluding any Selling Expenses, are called “Registration
Expenses”. All underwriting discounts and selling commissions applicable to the sale of Registrable Securities are called “Selling Expenses.” 

(b) The Company will pay all Registration Expenses incurred in connection with any registration pursuant to Section 2.3,
2.4 or 2.5; provided, however, if any registration requested pursuant to Section 2.3 or 2.5 is withdrawn at the request of the holders initiating such registration, such holders may elect to (i) have the Company pay the
Registration Expenses for such withdrawn registration but such withdrawn registration shall count as a completed registration toward the Company’s obligation pursuant to Section 2.3(b) or 2.5(a), as the case may be, or (ii) pay the
Registration Expenses for such withdrawn registration but such withdrawn registration shall not count as a completed registration toward the Company’s obligation under Section 2.3(b) or 2.5(a), as the case may be; provided
further, however, that if a registration is withdrawn after the holders of Registrable Securities initiating such registration have learned of a material adverse change in the financial condition or prospects of the Company or have
learned of other material adverse information relating to the Company, in either case not known to such holders at the time of their request for such registration, then all Registration Expenses related to such withdrawn registration shall be borne
by the Company and such withdrawn registration shall not be counted as a completed registration under Section 2.3(b) or 2.5(a), as the case may be. All Selling Expenses in connection with each registration statement under Section 2.3, 2.4
or 2.5 shall be borne by the participating sellers in proportion to the number of shares sold by each, or by such participating sellers other than the Company as they may agree. 

2.8 Indemnification and Contribution.  

(a) In connection with a registration of any of the Registrable Securities under the Securities Act pursuant to Section 2.3,
2.4 or 2.5, the Company will indemnify and hold harmless each seller of Registrable Securities, its officers, directors and partners, each underwriter of such Registrable Securities thereunder and each other person, if any, who controls such holder
or underwriter within the meaning of the Securities Act, against any losses, claims, damages or liabilities, joint or several, to which such holder, officer, director, partner, underwriter or controlling person may become subject under the
Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of any material fact contained in any prospectus,
offering circular or other document incident to such registration (including any related notification, registration statement under which such Registrable Securities were registered under the Securities Act pursuant to Section 2.3, 2.4 or 2.5, any
preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereof), (ii) any blue sky application or other document executed by the Company specifically for that purpose or based upon written information furnished
by the Company filed in any state or other jurisdiction in order to qualify any or all of the Registrable Securities under the securities laws thereof (any such application, document or information herein called a “Blue Sky
Application”), (iii) any omission or alleged omission to state in any such registration statement, prospectus, amendment or supplement or in any Blue Sky Application executed or filed by the Company, a material fact required to be
stated therein or necessary to make the statements therein not misleading, (iv) any violation by the Company or its agents of the Securities Act or any rule or regulation promulgated under the Securities Act applicable to the Company or its agents
and relating to action or inaction required of the Company in connection with such registration, or (v) any failure to register or qualify the Registrable Securities in any state where the Company or its agents has affirmatively undertaken or agreed
in writing that the Company (the undertaking of any underwriter chosen by the Company being attributed to the Company) will undertake such registration or qualification (provided that in such instance the Company shall not be so liable if it has
used its best efforts to so register or qualify the Registrable Securities) and will reimburse each such seller, and such officer, director and partner, each such underwriter and each such controlling person for any legal or other expenses
reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action, promptly after being so incurred, provided, however, that the Company will not be liable in any such case for
any amounts paid in settlement of any losses, claims, damages or liabilities if such settlement is effected without the consent of the Company, which consent shall not be 

  
 7 

 
unreasonably withheld, and, provided further, however, that the Company will not be liable in any such case if and to the extent that any such loss, claim, damage or
liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with written information furnished by any such holder, any such underwriter or any such controlling person
in writing specifically for use in such registration statement or prospectus. 
 (b) In connection with a registration of
any of the Registrable Securities under the Securities Act pursuant to Section 2.3, 2.4 or 2.5, each seller of such Registrable Securities thereunder, severally and not jointly, will indemnify and hold harmless the Company, each person, if any,
who controls the Company within the meaning of the Securities Act, each officer of the Company, each director of the Company, each other seller of Registrable Securities, each underwriter and each person who controls any underwriter within the
meaning of the Securities Act, against all losses, claims, damages or liabilities, joint or several, to which the Company or such officer, director, other seller, underwriter or controlling person may become subject under the Securities Act or
otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in any prospectus, offering circular or
other document incident to such registration (including any related notification, registration statement under which such Registrable Securities were registered under the Securities Act pursuant to Section 2.3, 2.4 or 2.5, any preliminary
prospectus or final prospectus contained therein, or any amendment or supplement thereof), or any Blue Sky Application or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading, and will reimburse the Company and each such officer, director, other seller, underwriter and controlling person for any legal or other expenses reasonably incurred by them in connection
with investigating or defending any such loss, claim, damage, liability or action, promptly after being so incurred, provided, however, that such seller will be liable hereunder in any such case if and only to the extent that any such
loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information pertaining to such seller, as such, furnished in
writing to the Company by such seller specifically for use in such registration statement or prospectus and, provided that, in no event shall such seller be liable for any amounts paid in settlement of any losses, claims, damages or liabilities if
such settlement is effected without the consent of such seller, which consent shall not be unreasonably withheld, and provided further, however, that the liability of each seller hereunder shall be limited to the proportion of
any such loss, claim, damage, liability or expense which is equal to the proportion that the public offering price of the securities sold by such seller under such registration statement bears to the total public offering price of all securities
sold thereunder, but not in any event to exceed the proceeds received by such seller from the sale of Registrable Securities covered by such registration statement. Not in limitation of the foregoing, it is understood and agreed that the
indemnification obligations of any seller hereunder pursuant to any underwriting agreement entered into in connection herewith shall be limited to the obligations contained in this subparagraph (b). 

(c) Promptly after receipt by an indemnified party hereunder of notice of the commencement of any action, such indemnified
party shall, if a claim in respect thereof is to be made against the indemnifying party hereunder, notify the indemnifying party in writing thereof, but the omission so to notify the indemnifying party shall not relieve it from any liability which
it may have to such indemnified party unless and to the extent the indemnifying party is prejudiced by such omission. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the
commencement thereof, the indemnifying party shall be entitled to participate in and, to the extent it shall wish, to assume and undertake the defense thereof with counsel satisfactory to such indemnified party and, after notice from the
indemnifying party to such indemnified party of its election so to assume and undertake the defense thereof, the indemnifying party shall not be liable to such indemnified party under this Section 2.8 for any legal expenses subsequently
incurred by such indemnified party in connection with the defense thereof, provided, however, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have
reasonably concluded that there may be reasonable defenses available to it which are different from or additional to those available to the indemnifying party or that the interests of the indemnified party reasonably may be deemed to conflict with
the interests of the indemnifying party, the indemnified party (together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to select one separate counsel and to assume such legal
defenses and otherwise to participate in the defense of such action, with the expenses and fees of such separate counsel and other reasonable expenses related to such participation to be reimbursed by the indemnifying party as incurred. No
indemnifying party, in the defense of any such claim or action, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or action. Each indemnified party shall furnish such information regarding itself or the claim in question as an indemnifying
party may reasonably request in writing and as shall be reasonably required in connection with defense of such claim and litigation resulting therefrom. 

(d) In order to provide for just and equitable contribution to joint liability under the Securities Act in any case in which
either (i) any holder of Registrable Securities exercising rights under this Agreement, or any controlling person of any such holder, 

  
 8 

 
makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any such selling holder or any such controlling person in circumstances for which indemnification is provided under this Section 2.8; then, and in each such case,
the Company and such holder will contribute to the aggregate losses, claims, damages or liabilities to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of the indemnifying
party on the one hand and the indemnified party on the other hand in connection with the actions or omissions which resulted in such losses, claims, damages or liabilities (or actions or proceedings in respect thereof), as well as any other
equitable considerations, it being understood that the relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact
or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or
prevent such statement or omission, provided, however, that, in any such case, (A) no such holder of Registrable Securities will be required to contribute any amount in excess of the proceeds received from the sale of all such
Registrable Securities offered by it pursuant to such registration statement; and (B) no person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution
from any person or entity who was not guilty of such fraudulent misrepresentation. 
 (e) The indemnities and obligations
provided in this Section 2.8 shall survive the transfer of any Registrable Securities by such holder effected in accordance with this Agreement or the termination of any registration rights granted hereunder. 

2.9 Changes in Common Stock. If, and as often as, there is any change in the Common Stock by way of a stock split, stock dividend,
combination or reclassification, or through a merger, consolidation, reorganization or recapitalization, or by any other means, appropriate adjustment shall be made in the provisions hereof so that the rights and privileges granted hereby shall
continue with respect to the Common Stock as so changed. 
 2.10 Rule 144 and 144A Reporting. With a view to making available the
benefits of certain rules and regulations of the Commission which may at any time permit the sale of the Registrable Securities to the public without registration, at all times after any registration statement covering a public offering of
securities of the Company under the Securities Act shall have become effective, the Company agrees to: 
 (a) use its best
efforts to comply with all of the reporting requirements of the Exchange Act and shall use its best efforts to comply with all other public information reporting requirements of the Commission as a condition to the availability of an exemption from
the Securities Act for the sale of any of the Registrable Securities by any holder of Registrable Securities (including any such exemption pursuant to Rule 144 or Rule 144A thereof); 

(b) cooperate with each holder of Registrable Securities in supplying such information as may be necessary for such holder of
Registrable Securities to complete and file any information reporting forms presently or hereafter required by the Commission as a condition to the availability of an exemption from the Securities Act (under Rule 144 or Rule 144A thereunder or
otherwise) for the sale of any of the Registrable Securities by any holder of Registrable Securities; and 
 (c) furnish to
each holder of Registrable Securities forthwith upon request a written statement by the Company as to its compliance with the reporting requirements of Rule 144 or Rule 144A (or any successor rule), and such information as such holder may reasonably
request in availing itself of any rule or regulation of the Commission allowing such holder to sell any Registrable Securities without registration. 

2.11 [Reserved].  

2.12 “Market Stand-Off” Agreement. Each of the Stockholders hereby agrees, severally and not jointly, if requested by the
Company and an underwriter of securities of the Company, not to directly or indirectly sell, offer to sell, contract to sell (including, without limitation, any short sale or other similar hedging transaction), grant any option to purchase or
otherwise transfer or dispose of (other than to transferees who agree to be similarly bound) any Common Stock or securities of the Company convertible into capital stock of the Company held by such Stockholder (but excluding any shares acquired in
or following the Initial Offering) during the one hundred and eighty (180) day period following the effective date of the registration statement for the Initial Offering and to enter into a written agreement with such underwriter to that effect,
provided that: 

  
 9 

 (a) all executive officers and directors of the Company and all holders of five
percent (5%) or greater of the outstanding capital stock of the Company enter into similar agreements; and 
 (b) the
Company uses its reasonable efforts to cause the managing underwriter to agree to permit periodic early releases of the capital stock of the Company held by the Stockholders that is subject to the foregoing restrictions and, in the event that the
managing underwriter permits such early releases, the capital stock of the Company held by all Stockholders is released on a pro rata basis (providing such managing underwriter will not be required to effect any pro rata release unless and until
such managing underwriter has first released more than three percent (3%) of the Company’s total outstanding shares from such lock-up). 

The Company may impose stop-transfer instructions with respect to the shares (or securities) subject to the foregoing
restriction until the end of said period. Each of the Stockholders agrees to sign such agreements or documents reasonably requested by the Company and/or the managing underwriters relating to and consistent with the provisions of this
Section 2.12. 
 2.13 Limitation on Subsequent Registration Rights. The Company shall not grant to any Person any registration
rights without the consent of the Requisite Investors, other than registration rights that are subordinate to or on parity with the registration rights contained herein. 

2.14 Assignment of Registration Rights. Notwithstanding any provision of this Agreement to the contrary, the rights to cause the
Company to register Registrable Securities pursuant to this Section 2 may be assigned (but only with all related obligations) by a holder of Registrable Securities to a transferee or assignee of such securities who, after such assignment or
transfer, holds at least 200,000 shares of such class or series of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations and other recapitalizations effected following the closing of the Initial
Offering), or such lesser number of shares if such number represents all shares of Registrable Securities held by the holder transferring such Registrable Securities; provided that the Company is, within a reasonable time after such transfer,
furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; and provided further, that the transferee or assignee shall
acknowledge in writing that the transferred or assigned Registrable Securities shall remain subject to this Agreement. Notwithstanding the foregoing, a holder of Registrable Securities may assign its rights under this Section 2 in accordance
with the preceding sentence to any Affiliate, member, principal, director, partner or stockholder of such holder (including spouses and ancestors, lineal descendants and siblings of such members, principals, directors, partners or stockholders who
acquire Registrable Securities by gift, will or intestate succession) without regard to the minimum share requirement set forth above. 

2.15 Termination of Registration Rights. The Company’s obligations under Sections 2.3, 2.4 and 2.5 to register the Registrable
Securities shall terminate on the second (2nd) anniversary of the closing of the Initial Offering. In addition, a Stockholder’s registration rights under this Section 2 shall expire
if all Registrable Securities held by and issuable to such Stockholder may be sold under Rule 144 during any ninety (90)-day period. 

SECTION 3. CERTAIN COVENANTS 
 3.1
Qualified Small Business. The Company shall submit to its stockholders and to the Internal Revenue Service any reports that may be required under Section 1202(d)(1)(C) of the Internal Revenue Code (the “Code”) and
the regulations promulgated thereunder. In addition, within ten (10) days after an Investor’s written request therefor, the Company shall furnish such Investor with a written statement informing such Investor whether such Investor’s
Registrable Securities constitute “Qualified Small Business Stock” (as defined in Section 1202(c) of the Internal Revenue Code of 1986, as amended). 

SECTION 4. MISCELLANEOUS.  

4.1 Notices. All notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the
receiving party’s address set forth below or to such other address as a party may designate by notice hereunder, and shall be either (i) delivered by hand, (ii) made by electronic mail or facsimile transmission, (iii) sent by
overnight courier or (iv) sent by registered or certified mail, return receipt requested, postage prepaid. 
 If to the Company: 

HTG Molecular Diagnostics, Inc. 

3430 E. Global Loop 

  
 10 

 
					
	 Tucson, AZ 85706
		
	 Attn: President
		
	 Phone:
		(877) 289-2615		
	 Fax:
		(520) 547-2837		

 With a copy to: 

 

					
	Cooley LLP		
	4401 Eastgate Mall		
	San Diego, CA 92121		
	Attn: Steve M. Przesmicki, Esq.		
	Phone:		(858) 550-6070		
	Fax:		(858) 550-6420		

 If to the Common Stockholders: To the addresses set forth on Exhibit A-1 hereto. 

If to the Investors: To the addresses set forth on Exhibit A-2 hereto. 

All notices, requests, consents and other communications hereunder shall be deemed to have been given either (i) if by hand, at the time
of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if made by electronic mail or facsimile transmission, at the time that receipt thereof has been acknowledged by electronic confirmation or
otherwise, if sent during normal business hours of the recipient, and if not send during normal business hours of the recipient, then on the next business day, (iii) if sent by overnight courier, on the next business day (or if sent overseas,
on the second (2nd) business day) following the day such notice is delivered to the courier service or (iv) if sent by registered or certified mail, on the fifth (5th) business day (or if sent overseas, on the tenth
(10th) business day) following the day such mailing is made. 
 4.2 Entire Agreement. This Agreement embodies the entire
agreement and understanding between the parties hereto with respect to the subject matter hereof and supersede all prior oral or written agreements and understandings relating to the subject matter hereof, including, without limitation, the Prior
Agreement. No statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement. 

4.3 Waivers and Amendment. Except as otherwise expressly provided, any term of this Agreement may be amended and the observance of any
term of this Agreement may be waived (either generally or in any particular instance), only with the written consent of the Company and the Requisite Investors. Notwithstanding the foregoing, (A) (i) any amendment or waiver of the
definition of Registrable Securities or of Section 2.4 that would have the effect of eliminating the right of Common Stockholders to include Registrable Securities pursuant to Section 2.4 in a registration, (ii) any amendment or
waiver of the last sentence of Section 1.1 or of Sections 2.1, 2.2, 2.8 or 2.12, (iii) any amendment or waiver of any other provision of this Agreement that would impose additional obligations on the Common Stockholders without imposing
similar obligations on the Investors or would adversely affect the rights or obligations of Common Stockholders without having a similar adverse effect on the rights of the Investors, and (iv) any amendment or waiver of the foregoing clauses
(i), (ii), (iii) and this clause (iv), shall also require the written consent of Common Stockholders holding at least a majority of the then outstanding Registrable Securities held by all Common Stockholders, and (B) the right of any
Stockholder may be waived to the extent that such waiver applies solely to such Stockholder’s rights by such Stockholder. Any waiver or amendment effected in accordance with the terms hereof shall be binding upon all Stockholders and the
Company. Upon the effectuation of each such waiver or amendment, the Company shall promptly give written notice thereof to the Stockholders who have not previously consented thereto in writing. 

4.4 Assignment. The rights and obligations under this Agreement may not be assigned by the Company or any Common Stockholder without
the prior written consent of the Requisite Investors, unless pursuant to a transfer of Registrable Securities specifically permitted by the terms hereof. 

4.5 Benefit. All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties
hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this Agreement shall be construed to create any rights or obligations except among the parties hereto, and no person or entity
shall be regarded as a third-party beneficiary of this Agreement, except indemnitees pursuant to Article 2 hereof. 

  
 11 

 4.6 Governing Law. This Agreement shall be construed and enforced in accordance with and
governed by the State of Delaware, without giving effect to the conflicts of law principles thereof. 
 4.7 Severability. In the
event that any court of competent jurisdiction shall determine that any provision, or any portion thereof, contained in this Agreement shall be unenforceable in any respect, then such provision shall be deemed limited to the extent that such court
deems it enforceable, and as so limited shall remain in full force and effect. In the event that such court shall deem any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this Agreement shall nevertheless remain
in full force and effect. 
 4.8 Interpretation. The parties hereto acknowledge and agree that: (i) each party and its counsel
reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting party shall not be employed in the
interpretation of this Agreement; and (iii) the terms and provisions of this Agreement shall be construed fairly as to all parties hereto and not in favor of or against any party, regardless of which party was generally responsible for the
preparation of this Agreement. 
 4.9 Headings and Captions. The headings and captions of the various subdivisions of this Agreement
are for convenience of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof. All pronouns used in this Agreement shall be deemed to include masculine, feminine and neuter forms, the
singular number includes the plural and the plural number includes the singular. 
 4.10 Enforcement. Each of the parties hereto
acknowledges and agrees that the rights acquired by each party hereunder are unique and that irreparable damage would occur in the event that any of the provisions of this Agreement to be performed by the other parties were not performed in
accordance with their specific terms or were otherwise breached. Accordingly, in addition to any other remedy to which the parties hereto are entitled at law or in equity, each party hereto shall be entitled to an injunction or injunctions to
prevent breaches of this Agreement by any other party and to enforce specifically the terms and provisions hereof in any federal or state court to which the parties have agreed hereunder to submit to jurisdiction. 

4.11 No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under
this Agreement, and no course of dealing among the parties hereto, shall operate as a waiver of any such right, power or remedy of the party. No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any
abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a
party hereto shall not constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Agreement shall entitle the party receiving such notice or demand to any
other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand. 

4.10 Counterparts. This Agreement may be executed in one or more counterparts, and by different parties hereto on separate
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of signatures by facsimile or PDF will be as effective as the delivery of original signatures. 

4.11 Aggregation of Stock. All shares of Registrable Securities held by any Stockholder and its Affiliates shall be aggregated for
determining the availability of any rights under this Agreement. 
 4.12 Confidentiality. Each Investor agrees to hold all
confidential information received pursuant to this Agreement in confidence, and not to use or disclose any of such information to any third party, except to the extent that such information may be made publicly available by the Company and other
than to monitor and maintain its investment in the Company; provided, however, that any Investor may, in the ordinary course of business, provide the financial results of the Company to its stockholders, partners or members in the same manner such
information is provided by such Investor with respect to its portfolio companies. 
 4.13 Section References. References herein to
“Articles” and “Sections” herein shall be to Articles and Sections of this Agreement. 
 [REMAINDER
OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 12 

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

			
	COMPANY:
	
	HTG MOLECULAR DIAGNOSTICS, INC.
		
	Signature:		 /s/ Timothy Johnson

	Print Name:		Timothy Johnson
	Title:		President and Chief Executive
Officer

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

			
	INVESTOR:
	
	S.R. ONE, LIMITED
		
	By:		 /s/ Simeon J. George

	Name: Simeon J. George
	Title: Vice President and Partner

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

			
	 INVESTOR:

	
	 NOVO A/S

		
	 By:
		 /s/ Jack B. Nielsen

	 Name: Jack B. Nielsen

	 Title: Partner

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

			
	 INVESTOR:

	
	 Fletcher Spaght Ventures II, L.P.

	 By: Fletcher Spaght Associates II, L.P., its General Partner

	 By: FSA II, LLC, its General Partner

		
	 By:
		 /s/ R. John Fletcher

		
	 Name:
		 R. John Fletcher

	
	 Title: Managing Member

	
	 FSV II, L.P.

	 By: Fletcher Spaght Associates II, L.P., its General Partner

	 By: FSA II, LLC, its General Partner

		
	 By:
		 /s/ R. John Fletcher

		
	 Name:
		 R. John Fletcher

	
	 Title: Managing Member

	
	 FSV II-B, L.P.

	 By: Fletcher Spaght Associates II-B, LLC, its General Partner

	 By: FSA II, LLC, its Manager

		
	 By:
		 /s/ R. John Fletcher

		
	 Name:
		 R. John Fletcher

	
	 Title: Managing Member

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

			
	 INVESTOR:

	
	 MERCK CAPITAL VENTURES, LLC

		
	 By:
		 /s/ Lawrence D. Senour

	 Name: Lawrence D. Senour

	 Title: Executive Director, Corporate Development

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

			
	 INVESTOR:

	
	 SOLSTICE CAPITAL II, L.P.

	 By: Solstice Capital LLC, its general partner

		
	 By:
		 /s/ Harry A. George

	 Name: Harry A. George

	 Title: Managing Member

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

	
	 INVESTOR:

	
	 /s/ Jim Weersing

	 JIM WEERSING, TRUSTEE OF THE
WEERSING

	 FAMILY TRUST

 IN WITNESS WHEREOF, the
parties hereto have executed this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof.

  

					
			COMMON STOCKHOLDERS:		
			
			 /s/ Bruce Seligman
		
			 BRUCE SELIGMANN, TRUSTEE OF THE
SELIGMANN-JUNGHANS
 FAMILY TRUST U/A/D JULY 9, 1999

			
			 /s/ Bruce Seligman
		
			BRUCE SELIGMANN		

 EXHIBIT A-1 

COMMON STOCKHOLDERS 
  

					
	 NAME AND ADDRESS OF

 
 STOCKHOLDER
		
COMMON STOCK
  
		
OPTIONS
  

	 Seligmann-Junghans
Family
 Trust U/A/D July 9, 1999
 Address on file with
Company
  
		5,105,714		 
	 Ralph R. Martel

Address on file with Company
  
		140,000		 
	 Constance A.
Junghans
 Address on file with Company
  
		498,130		 
	 Timothy B.
Johnson
 Address on file with Company
  
		 		11,863,118
	 Bruce Seligmann

Address on file with Company
  
		657,000		1,859,510
	 Pete Clemens

Address on file with Company
  
		138,750		 
	 Shaun McMeans

Address on file with Company
  
		 		2,499,162
	 John Lubniewski

Address on file with Company
  
		 		3,476,196
	 Stephen Hagan

Address on file with Company
  
		 		1,915,969
	 Debra Gordon

Address on file with Company
  
		 		893,840
	 Donald Ball

Address on file with Company
  
		 		746,710
	 Vijay Modur

Address on file with Company
  
		 		2,599,162

 EXHIBIT A-2 

INVESTORS 
  

													
	
NAME AND ADDRESS OF
  

STOCKHOLDER
		   SERIES  

 
 A
		  SERIES B  		   SERIES  

 
 C-1
		   SERIES  

 
 C-2
		  SERIES D  		  SERIES E  
	 S.R. One,
Limited
 Address on file with Company

 
		 		 		 		 		36,546,366		15,227,653
	 NOVO
A/S
 Address on file with Company
  
		 		 		 		 		50,251,254		15,227,653
	 Fletcher Spaght Ventures II, L.P. c/o Fletcher

Address on file with Company
  
		 		 		 		 		16,801,503		3,862,416
	 FSV II,
L.P.
 c/o Fletcher Spaght, Inc./ Fletcher Spaght

Ventures

Address on file with Company
  
		 		 		 		 		1,692,017		388,969
	 FSV II-B,
L.P.
 c/o Fletcher Spaght, Inc./ Fletcher Spaght

Ventures

Address on file with Company
  
		 		 		 		 		8,002,596		1,839,677
	 MERCK
CAPITAL VENTURES, LLC
 Address on file with Company

 
 WITH A COPY TO:

 
 Edwards Angell Palmer & Dodge

Address on file with Company
  
		 		 		8,670,520		9,601,924		20,658,958		7,613,826
	  

Solstice Capital II, L.P.

Address on file with Company
  
		574,212		4,183,874		1,547,390		4,157,017		1,888,295		 
	 Valley
Ventures III, L.P.
 Address on file with Company

 
		459,369		3,616,906		516,010		992,890		586,281		 
	 Valley
Ventures III Annex, L.P.
 Address on file with Company

 
		 		 		1,083,815		2,978,666		1,758,843		 

													
	 NAME AND ADDRESS OF

 
 STOCKHOLDER
		
  SERIES  
  

A
		  SERIES B  		
  SERIES  
  

C-1
		
  SERIES  
  

C-2
		  SERIES D  		  SERIES E  
	 Village Ventures Partners Fund, L.P.

Address on file with Company
  

With a copy to:
  

Village Ventures, Inc.
 Address on file with Company

 
		106,227		768,556		286,254		 		 		 
	 Village Ventures Partners Fund A, L.P.

c/o Village Ventures, Inc.
 Address on file with Company

 
 With a copy to:

 
 Village Ventures, Inc.

Address on file with Company
  
		8,041		58,199		21,675		 		 		 
	 VVN, LLC

c/o Village Ventures, Inc.
 Address on file with Company

 
 With a copy to:

 
 Village Ventures, Inc.

Address on file with Company
  
		574		4,154		1,547		 		 		 
	 GC&H INVESTMENTS, LLC

Address on file with Company
  
		 		 		72,254		 		90,394		 
	 ETP/FBR Venture Capital II, LLC

Address on file with Company
  
		 		691,227		308,527		 		 		 
	 PALICE INVESTMENTS, LLC

Address on file with Company
  
		 		 		380,829		 		238,220		 
	 415 Golf View LLC

c/o Granger L. Vinall
 Address on file with Company

 
		 		 		37,085		 		 		 
	 Miramar Ventures, LLC

c/o David C. Smallhouse
 Address on file with Company

 
		 		164,577		314,915		 		 		 
	 Steven P. Sim and Marilyn B. Einstein

Address on file with Company
  
		 		65,138		148,341		 		 		 
	 Edward B. Berger and Christina McComb-

Berger Family Trust dated December 6, 2002
 c/o Edward B.
Berger and Christina McComb-Berger Family Trust
 Address on file with Company

 
		 		82,165		74,170		 		 		 

													
	
NAME AND ADDRESS OF
  

STOCKHOLDER
		   SERIES  

 
 A
		  SERIES B  		   SERIES  

 
 C-1
		   SERIES  

 
 C-2
		  SERIES D  		  SERIES E  
	 Curtis Gunn

Address on file with Company
  
		 		32,611		451,923		 		 		 
	 Weintraub Family Trust W/A dtd 03/13/80

Ronald H. Weintraub &
Diane B. Weintraub,

Trustees
 Address on file with Company

 
		 		65,831		74,154		 		 		 
	 Pierre Sice & Genevieve Sice, Community

Property
 Address on file with Company

 
		 		101,205		 		 		95,164		 
	 Pierre Sice

Address on file with Company
  
		 		 		73,917		 		 		 
	 Ralph R. Martel

Address on file with Company
  
		 		 		44,212		 		 		 
	 Lawrence J. Aldrich

Address on file with Company
  
		 		 		44,212		 		27,656		 
	 E. William Radany

Address on file with Company
  
		 		 		44,212		 		 		 
	 Bruce Seligmann

Address on file with Company
  
		143,661		 		 		 		 		 
	 ARCTURUS CAPITAL VENTURE FUND,

L.P.
 Address on file with Company

 
		 		 		1,445,087		1,108,156		 		 
	 The Second Sonenblick Family Limited

Partnership
 Address on file with Company

 
		 		32,915		72,254		 		 		 
	 Pete Clemens

Address on file with Company
  
		 		 		 		44,326		 		 
	 Weersing Family Trust

Address on file with Company
  
		 		 		 		 		1,867,969		609,106
	 Bruce Seligmann, Trustee of the Seligmann-

Junghans Family Trust U/A/D July 9, 1999
 Address on file
with Company
  
		 		123,228		44,157		 		119,288		 
	 Timothy B. Johnson

Address on file with Company
  
		 		 		 		221,631		233,495		60,910
	 Constance Junghans

Address on file with Company
  
		 		 		44,212		 		119,288		 

													
	
NAME AND ADDRESS OF
  

STOCKHOLDER
		   SERIES  

 
 A
		  SERIES B  		   SERIES  

 
 C-1
		   SERIES  

 
 C-2
		  SERIES D  		  SERIES E  
	 Kirk Collamer

Address on file with Company
  
		 		 		44,212		 		119,288		 
	 BJ Kerns

Address on file with Company
  
		 		 		 		 		23,857		 
	 John Luecke

Address on file with Company
  
		 		 		 		 		11,928		 
	 Fredrick Pollock

Address on file with Company
  
		 		 		 		 		4,771		 
	 Kathleen Toolan

Address on file with Company
  
		 		 		 		 		119,288		 
	 Bernice Junghans

Address on file with Company
  
		 		 		 		 		119,288		 
	 Sharyl Cummings & Steve Blomquist

Address on file with Company
  
		 		 		 		 		119,288		 
	 Huw R. Jones and Cynthia D. Heydon-Jones

Address on file with Company
  
		 		 		 		 		238,577		 
	 Douglas E. Marsh 401(k) Profit Sharing Plan

Address on file with Company
  
		 		 		 		 		71,573		 
	 James Glinn

Address on file with Company
  
		 		 		 		 		861,723		 
	 Basil E. Horner

Address on file with Company
  
		 		 		 		 		23,857		 
	 Jerry Sonenblick

Address on file with Company
  
		 		 		 		 		47,715		 
	 Edward Michael Gloyne

Address on file with Company
  
		 		164,577		148,341		 		238,577		 
	 Phillip Chu

Address on file with Company
  
		 		 		 		 		119,288		 
	 John Wineman

Address on file with Company
  
		 		 		 		 		91,366		 
	 Tom Vasicek

Address on file with Company
  
		 		 		 		 		22,841		 

													
	
NAME AND ADDRESS OF
  

STOCKHOLDER
		   SERIES  

 
 A
		  SERIES B  		   SERIES  

 
 C-1
		   SERIES  

 
 C-2
		  SERIES D  		  SERIES E  
	 Danilo Cacciamatta

Address on file with Company
  
		 		100,964		 		 		 		 
	 DBD Fund, Inc.

Address on file with Company
  
		 		81,246		 		 		 		 
	 Deimos Ventures, LLC

Address on file with Company
  
		 		645,161		 		 		 		 
	 Holualoa Arizona, Inc.

Address on file with Company
  
		 		162,386		 		 		 		 
	 Margaret King Joukowsky

Address on file with Company
  
		 		36,895		 		 		 		 
	 William H. Lomicka

Address on file with Company
  
		 		81,069		 		 		 		 
	 Tucson Pharma Ventures, LLC

Address on file with Company
  
		 		32,555		 		 		 		 
	 Daniel D. Von Hoff, M.D.

Address on file with Company
  
		 		81,528		 		 		 		 
	 BSE Trust

Address on file with Company
  
		 		82,289		 		 		 		 
	 Fairfax Management Company, LLC

Address on file with Company
  
		 		65,831		 		 		 		 
	 Artemis Joukowsky III

Address on file with Company
  
		 		45,093		 		 		21,800		 
	 John Lubniewski

Address on file with Company
  
		 		 		 		 		228,414		76,138
	 Shaun McMeans

Address on file with Company
  
		 		 		 		 		114,207		152,276
	 Stephen Hagan

Address on file with Company
  
		 		 		 		 		114,207		60,910
	 Debra Gordon

Address on file with Company
  
		 		 		 		 		25,124		 
	 Julie Capadona

Address on file with Company
  
		 		 		 		 		1,133		 
	 Elsie L. Elliott

Address on file with Company
  
		 		 		 		 		20,954		 

													
	
NAME AND ADDRESS OF
  

STOCKHOLDER
		   SERIES  

 
 A
		  SERIES B  		   SERIES  

 
 C-1
		   SERIES  

 
 C-2
		  SERIES D  		  SERIES E  
	 Jeffrey R. Lee

Address on file with Company
  
		 		 		 		 		764		 
	 Tamara Morrissy

Address on file with Company
  
		 		 		 		 		52		 
	 Donald Ball

Address on file with Company
  
		 		 		 		 		 		30,456
	 David and Shaila Silverio, JTWROS

Address on file with Company
  
		 		 		 		 		 		60,910
	 Todd McMeans

Address on file with Company
  
		 		 		 		 		 		152,276
	 Desert Sidecar IV, LLC

c/o Curtis Gunn
 Address on file with Company

 
		 		 		 		 		 		102,786

 March 19, 2015 

HTG Molecular Diagnostics, Inc. 
 3430 E. Global Loop 

Tucson, AZ 85706 
 Attn: Timothy B. Johnson, President and Chief
Executive Officer 
 Dear Mr. Johnson: 
 Reference is
made to that certain Amended and Restated Investor Rights Agreement, dated December 22, 2014, by and among HTG Molecular Diagnostics, Inc. (the “Company”), certain holders of common stock of the Company listed on Exhibit
A-1 thereto and the holders of preferred stock of the Company listed on Exhibit A-2 thereto (the “Agreement”). All capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Agreement.

 Pursuant to Section 1.1 of the Agreement, the Agreement shall be null and void and the Prior Agreement shall remain in full force and effect if the
Initial Offering is not completed for any reason by March 31, 2015 (the “Sunset Date”) (or such later date as consented to by the Requisite Investors (as such term is defined in the Prior Agreement)). Pursuant to
Section 1.1 of the Agreement, this letter shall serve as written notice that the undersigned stockholders of the Company, constituting the Requisite Investors, hereby consent to extend the Sunset Date from March 31, 2015 to June 30,
2015. 
 Sincerely, 
  

			
	NOVO A/S		S.R. ONE, LIMITED
		
	By: /s/ Jack B. Nielsen                    		By: /s/ Simeon J. George                    
	Name: Jack B. Nielsen		Name: Simeon J. George
	 Title: Partner
		Title: Vice President and Partner

 Agreed and Accepted as of March 19, 2015: 

HTG MOLECULAR DIAGNOSTICS, INC. 
  

	
	By: /s/ Timothy B. Johnson                    
	Name: Timothy B. Johnson
	Title: President and Chief Executive OfficerEX-10.4

 Exhibit 10.4 

HTG MOLECULAR DIAGNOSTICS, INC. 

2014 EQUITY INCENTIVE PLAN 

ADOPTED BY THE BOARD OF DIRECTORS:
DECEMBER 2, 2014 
 AMENDED BY THE BOARD
OF DIRECTORS: APRIL 23, 2015 
 APPROVED BY
THE STOCKHOLDERS: APRIL 24, 2015 
 IPO DATE:
[            ], 2015 
  

	1.	 GENERAL. 

(a)         Successor to and Continuation of Prior
Plan.    The Plan is intended as the successor to and continuation of the HTG Molecular Diagnostics, Inc. 2011 Equity Incentive Plan, as amended (the “2011 Plan”). From and after 12:01 a.m.
Pacific time on the IPO Date, no additional stock awards will be granted under the 2011 Plan. All Awards granted on or after 12:01 a.m. Pacific Time on the IPO Date will be granted under this Plan. All stock awards granted under the 2011 Plan or the
HTG Molecular Diagnostics, Inc. 2001 Stock Option Plan, as amended (collectively, the “Prior Plans”), will remain subject to the terms of the Prior Plans. 

(i)         Any shares that would otherwise remain available for
future grants under the 2011 Plan as of 12:01 a.m. Pacific Time on the IPO Date (the “2011 Plan’s Available Reserve”) will cease to be available under the 2011 Plan at such time. Instead, that number of shares of Common
Stock equal to the 2011 Plan’s Available Reserve will be added to the Share Reserve (as further described in Section 3(a) below) and will be immediately available for grants and issuance pursuant to Stock Awards hereunder, up to the
maximum number set forth in Section 3(a) below.  
 (ii)        
In addition, from and after 12:01 a.m. Pacific Time on the IPO Date, any shares subject, at such time, to outstanding stock awards granted under the Prior Plans that (i) expire or terminate for any reason prior to exercise or settlement;
(ii) are forfeited because of the failure to meet a contingency or condition required to vest such shares or otherwise return to the Company; or (iii) are reacquired, withheld (or not issued) to satisfy a tax withholding obligation in
connection with an award or to satisfy the purchase price or exercise price of a stock award (such shares the “Returning Shares”) will immediately be added to the Share Reserve (as further described in Section 3(a)
below) as and when such shares become Returning Shares, up to the maximum number set forth in Section 3(a) below. 

(b)         Eligible Award Recipients.    Employees,
Directors and Consultants are eligible to receive Awards. 
 (c)        
Available Awards.    The Plan provides for the grant of the following Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards,
(v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards. 

(d)         Purpose.    The Plan, through the grant of
Awards, is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such 

  
 1. 

 
persons to exert maximum efforts for the success of the Company and any Affiliate, and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.

  

	2.	 ADMINISTRATION. 

(a)        Administration by Board.    The Board
will administer the Plan. The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c). 

(b)        Powers of Board.    The Board will have
the power, subject to, and within the limitations of, the express provisions of the Plan: 

(i)        To determine: (A) who will be granted Awards; (B) when
and how each Award will be granted; (C) what type of Award will be granted; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock
under the Award; (E) the number of shares of Common Stock subject to, or the cash value of, an Award; and (F) the Fair Market Value applicable to a Stock Award. 

(ii)        To construe and interpret the Plan and Awards granted under it,
and to establish, amend and revoke rules and regulations for administration of the Plan and Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement or in the written
terms of a Performance Cash Award, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective. 

(iii)        To settle all controversies regarding the Plan and Awards granted
under it. 
 (iv)        To accelerate, in whole or in part, the time at
which an Award may be exercised or vest (or the time at which cash or shares of Common Stock may be issued in settlement thereof). 

(v)        To suspend or terminate the Plan at any time. Except as otherwise
provided in the Plan or an Award Agreement, suspension or termination of the Plan will not materially impair a Participant’s rights under the Participant’s then-outstanding Award without the Participant’s written consent, except as
provided in subsection (viii) below. 
 (vi)        To amend the Plan in any
respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or bringing the Plan or
Awards granted under the Plan into compliance with the requirements for Incentive Stock Options or ensuring that they are exempt from, or compliant with, the requirements for nonqualified deferred compensation under Section 409A of the Code,
subject to the limitations, if any, of applicable law. If required by applicable law or listing requirements, and except as provided in Section 9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any
amendment of the Plan that (A) materially increases the number of shares of Common Stock available for issuance under the Plan, (B) materially expands the class of individuals eligible to receive Awards under the Plan, (C) materially
increases the benefits 

  
 2. 

 
accruing to Participants under the Plan, (D) materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (E) materially extends the term of
the Plan, or (F) materially expands the types of Awards available for issuance under the Plan. Except as otherwise provided in the Plan or an Award Agreement, no amendment of the Plan will materially impair a Participant’s rights under an
outstanding Award without the Participant’s written consent. 

(vii)        To submit any amendment to the Plan for stockholder approval,
including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A) Section 162(m) of the Code regarding the exclusion of performance-based compensation from the limit on corporate deductibility of
compensation paid to Covered Employees, (B) Section 422 of the Code regarding “incentive stock options” or (C) Rule 16b-3. 

(viii)        To approve forms of Award Agreements for use under the Plan and
to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not
subject to Board discretion; provided, however, that a Participant’s rights under any Award will not be impaired by any such amendment unless (A) the Company requests the consent of the affected Participant, and (B) such Participant
consents in writing. Notwithstanding the foregoing, (1) a Participant’s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not
materially impair the Participant’s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant’s consent (A) to maintain the
qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (B) to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the qualified
status of the Award as an Incentive Stock Option under Section 422 of the Code; (C) to clarify the manner of exemption from, or to bring the Award into compliance with, Section 409A of the Code; or (D) to comply with other
applicable laws or listing requirements. 
 (ix)        Generally, to
exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. 

(x)        To adopt such procedures and sub-plans as are necessary or
appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or
any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction). 

(xi)        To effect, with the consent of any adversely affected Participant,
(A) the reduction of the exercise, purchase or strike price of any outstanding Stock Award; (B) the cancellation of any outstanding Stock Award and the grant in substitution therefor of a new (1) Option or SAR, (2) Restricted
Stock Award, (3) Restricted Stock Unit Award, (4) Other Stock Award, (5) cash and/or (6) other valuable consideration determined by the Board, in its sole discretion, with any such substituted award (x) covering the same or
a different number of shares 

  
 3. 

 
of Common Stock as the cancelled Stock Award and (y) granted under the Plan or another equity or compensatory plan of the Company; or (C) any other action that is treated as a repricing
under generally accepted accounting principles. 
 (c)        Delegation to
Committee. 
 (i)        General.    The Board may
delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore
possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board
will thereafter be to the Committee or subcommittee, as applicable). Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as
applicable). The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. 

(ii)        Section 162(m) and Rule 16b-3
Compliance.    The Committee may consist solely of two or more Outside Directors, in accordance with Section 162(m) of the Code, or solely of two or more Non-Employee Directors, in accordance with Rule 16b-3. 

(d)        Delegation to an Officer.    The Board may
delegate to one (1) or more Officers the authority to do one or both of the following (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Stock Awards)
and, to the extent permitted by applicable law, the terms of such Awards, and (ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; provided, however, that the Board resolutions
regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself. Any such Stock Awards will be
granted on the form of Stock Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation authority. The Board may not delegate authority to an Officer who is
acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section 13(w)(iii) below. 

(e)        Effect of Board’s Decision.    All
determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. 

 

	3.	 SHARES SUBJECT TO THE PLAN. 

(a)        Share Reserve.    Subject to Section 9(a)
relating to Capitalization Adjustments, and the following sentence regarding the annual increase, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards will not exceed 1,534,435 shares (the “Share
Reserve”), which number is the sum of (i) 925,616 new shares, plus (ii) the number of shares subject to the 2011 Plan’s Available Reserve, plus (iii) the number of shares that are Returning Shares, as such
shares become available from time to time. 

  
 4. 

 In addition, the Share Reserve will automatically increase on January 1st of each year, for a period of not more than ten years from the date the Plan is approved by the stockholders of the Company, commencing on
January 1st of the year following the year in which the IPO Date occurs and ending on (and including) January 1, 2024, in an amount equal to 4% of the total number of shares of Capital
Stock outstanding on December 31st of the preceding calendar year. Notwithstanding the foregoing, the Board may act prior to
January 1st of a given year to provide that there will be no January 1st increase in the Share Reserve for such year or that the
increase in the Share Reserve for such year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence. For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of
shares of Common Stock that may be issued pursuant to the Plan. Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a). Shares may be issued in connection with a merger or acquisition
as permitted by NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for
issuance under the Plan. 
 (b)        Reversion of Shares to the Share
Reserve.    If a Stock Award or any portion thereof (i) expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or (ii) is settled in cash (i.e., the
Participant receives cash rather than stock), such expiration, termination or settlement will not reduce (or otherwise offset) the number of shares of Common Stock that may be available for issuance under the Plan. If any shares of Common Stock
issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased will
revert to and again become available for issuance under the Plan. Any shares reacquired by the Company in satisfaction of tax withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award will again
become available for issuance under the Plan. 
 (c)        Incentive Stock
Option Limit.    Subject to the provisions of Section 9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock
Options will be 1,800,000 shares of Common Stock. 

(d)        Section 162(m)
Limitations.    Subject to the provisions of Section 9(a) relating to Capitalization Adjustments, at such time as the Company may be subject to the applicable provisions of Section 162(m) of the Code,
the following limitations shall apply. 
 (i)        A maximum of 200,000
shares of Common Stock subject to Options, SARs and Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the Fair Market Value on the date the Stock Award is granted may be
granted to any one Participant during any one calendar year. Notwithstanding the foregoing, if any additional Options, SARs or Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least 100%
of the 

  
 5. 

 
Fair Market Value on the date the Stock Award are granted to any Participant during any calendar year, compensation attributable to the exercise of such additional Stock Awards will not satisfy
the requirements to be considered “qualified performance-based compensation” under Section 162(m) of the Code unless such additional Stock Award is approved by the Company’s stockholders. 

(ii)        A maximum of 200,000 shares of Common Stock subject to Performance
Stock Awards may be granted to any one Participant during any one calendar year (whether the grant, vesting or exercise is contingent upon the attainment during the Performance Period of the Performance Goals). 

(iii)        A maximum of $2,000,000 may be granted as a Performance Cash
Award to any one Participant during any one calendar year. 
 (e)        Source
of Shares.    The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise. 

 

	4.	 ELIGIBILITY. 

(a)        Eligibility for Specific Stock
Awards.    Incentive Stock Options may be granted only to employees of the Company or a “parent corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and 424(f) of
the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants; provided, however, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous
Service only to any “parent” of the Company, as such term is defined in Rule 405 of the Securities Act, unless (i) the stock underlying such Stock Awards is treated as “service recipient stock” under Section 409A of the
Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction), (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt
from Section 409A of the Code, or (iii) the Company, in consultation with its legal counsel, has determined that such Stock Awards comply with the distribution requirements of Section 409A of the Code. 

(b)        Ten Percent Stockholders. A Ten Percent Stockholder will not be
granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant. 

 

	5.	 PROVISIONS RELATING TO OPTIONS AND STOCK
APPRECIATION RIGHTS. 

 Each Option or SAR will be in such form and will
contain such terms and conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or
certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some
portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion 

  
 6. 

 
thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical; provided, however, that each Award Agreement will conform to (through
incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions: 

(a)        Term.    Subject to the provisions of
Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of ten years from the date of its grant or such shorter period specified in the Award Agreement. 

(b)        Exercise Price.    Subject to the provisions of
Section 4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award is granted.
Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Award if such Award is granted pursuant to an assumption of or substitution
for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A and, if applicable, Section 424(a) of the Code. Each SAR will be denominated in shares of
Common Stock equivalents. 
 (c)        Purchase Price for
Options.    The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of
the methods of payment set forth below. The Board will have the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the
consent of the Company to use a particular method of payment. The permitted methods of payment are as follows: 

(i)          by cash, check, bank draft or money order payable to
the Company; 
 (ii)         pursuant to a program developed under
Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate
exercise price to the Company from the sales proceeds; 
 (iii)        by
delivery to the Company (either by actual delivery or attestation) of shares of Common Stock; 

(iv)         if an Option is a Nonstatutory Stock Option, by a “net
exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price;
provided, however, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued.
Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the “net exercise,”
(B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or 

  
 7. 

 (v)        in any other form of
legal consideration that may be acceptable to the Board and specified in the applicable Award Agreement. 

(d)        Exercise and Payment of a SAR.    To exercise
any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a
SAR will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the
Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is
exercising the SAR on such date. The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such
SAR. 
 (e)        Transferability of Options and
SARs.    The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the
following restrictions on the transferability of Options and SARs will apply: 

(i)         Restrictions on Transfer.    An Option or
SAR will not be transferable except by will or by the laws of descent and distribution (or pursuant to subsections (ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. The Board may
permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration. 

(ii)        Domestic Relations Orders.    Subject to the
approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury
Regulations Section 1.421-1(b)(2). If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. 

(iii)        Beneficiary Designation.    Subject to the
approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, on the death of the Participant, will
thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, upon the death of the Participant, the executor or administrator of the
Participant’s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to
any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws. 

  
 8. 

 (f)        Vesting
Generally.    The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms
and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary.
The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised. 

(g)        Termination of Continuous Service.    Except as
otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates (other than for Cause and other than upon the Participant’s death or
Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Award as of the date of termination of Continuous Service) within the period of time ending on the earlier of
(i) the date three months following the termination of the Participant’s Continuous Service (or such longer or shorter period specified in the applicable Award Agreement), and (ii) the expiration of the term of the Option or SAR as
set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR will terminate. 

(h)        Extension of Termination Date.    If the
exercise of an Option or SAR following the termination of the Participant’s Continuous Service (other than for Cause and other than upon the Participant’s death or Disability) would be prohibited at any time solely because the issuance of
shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the
applicable post termination exercise period after the termination of the Participant’s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, and (ii) the expiration
of the term of the Option or SAR as set forth in the applicable Award Agreement. In addition, unless otherwise provided in a Participant’s Award Agreement, if the sale of any Common Stock received on exercise of an Option or SAR following the
termination of the Participant’s Continuous Service (other than for Cause) would violate the Company’s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of a period of months (that need
not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant’s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in
violation of the Company’s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement. 

(i)        Disability of Participant.    Except as
otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates as a result of the Participant’s Disability, the Participant may exercise his
or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months
following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii) the 

  
 9. 

 
expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the
applicable time frame, the Option or SAR (as applicable) will terminate. 

(j)        Death of Participant.    Except as otherwise
provided in the applicable Award Agreement or other agreement between the Participant and the Company, if (i) a Participant’s Continuous Service terminates as a result of the Participant’s death, or (ii) the Participant dies
within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant’s Continuous Service for a reason other than death, then the Option or SAR may be exercised (to the extent the Participant
was entitled to exercise such Option or SAR as of the date of death) by the Participant’s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR
upon the Participant’s death, but only within the period ending on the earlier of (i) the date 18 months following the date of death (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the
term of such Option or SAR as set forth in the Award Agreement. If, after the Participant’s death, the Option or SAR is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate. 

(k)        Termination for Cause.    Except as explicitly
provided otherwise in a Participant’s Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant’s Continuous Service is terminated for Cause, the Option or SAR will
terminate immediately upon such Participant’s termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service. 

(l)        Non-Exempt Employees.    If an Option or SAR is
granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of
grant of the Option or SAR (although the Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt Employee dies or suffers a Disability, (ii) upon a Corporate
Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant’s retirement (as such term may be defined in the Participant’s Award Agreement in
another agreement between the Participant and the Company, or, if no such definition, in accordance with the Company’s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than
six months following the date of grant. The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of
pay. To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock
Award will be exempt from the employee’s regular rate of pay, the provisions of this Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements. 

  
 10. 

	6.	 PROVISIONS OF STOCK AWARDS OTHER THAN
OPTIONS AND SARS. 

(a)        Restricted Stock Awards.    Each Restricted
Stock Award Agreement will be in such form and will contain such terms and conditions as the Board will deem appropriate. To the extent consistent with the Company’s bylaws, at the Board’s election, shares of Common Stock may be
(x) held in book entry form subject to the Company’s instructions until any restrictions relating to the Restricted Stock Award lapse; or (y) evidenced by a certificate, which certificate will be held in such form and manner as
determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. Each Restricted Stock Award
Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: 

(i)        Consideration.    A Restricted Stock Award may
be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration that may be acceptable to the Board, in
its sole discretion, and permissible under applicable law. 

(ii)        Vesting.    Shares of Common Stock awarded
under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board. 

(iii)        Termination of Participant’s Continuous
Service.    If a Participant’s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant that have not
vested as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement. 

(iv)        Transferability.    Rights to acquire shares
of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so
long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement. 

(v)        Dividends.    A Restricted Stock Award
Agreement may provide that any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate. 

(b)        Restricted Stock Unit Awards.    Each Restricted
Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board will deem appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and
conditions of separate Restricted Stock Unit Award Agreements need not be identical. Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance
of each of the following provisions: 

(i)        Consideration.    At the time of grant of a
Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of 

  
 11. 

 
each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit
Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. 

(ii)        Vesting.    At the time of the grant of a
Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate. 

(iii)        Payment.    A Restricted Stock Unit Award may
be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. 

(iv)        Additional Restrictions.    At the time of the
grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a
time after the vesting of such Restricted Stock Unit Award. 

(v)        Dividend Equivalents.    Dividend equivalents
may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may
be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend
equivalents will be subject to all of the same terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate. 

(vi)        Termination of Participant’s Continuous
Service.    Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant’s termination
of Continuous Service. 
 (c)        Performance Awards. 

(i)        Performance Stock Awards.    A Performance
Stock Award is a Stock Award (covering a number of shares not in excess of that set forth in Section 3(d) above) that is payable (including that may be granted, may vest or may be exercised) contingent upon the attainment during a Performance
Period of certain Performance Goals. A Performance Stock Award may, but need not, require the Participant’s completion of a specified period of Continuous Service. The length of any Performance Period, the Performance Goals to be achieved
during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section 162(m) of the Code, the
Board), in its sole discretion. In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards. 

  
 12. 

 (ii)        Performance Cash
Awards.    A Performance Cash Award is a cash award (for a dollar value not in excess of that set forth in Section 3(d) above) that is payable contingent upon the attainment during a Performance Period of certain
Performance Goals. A Performance Cash Award may also require the completion of a specified period of Continuous Service. At the time of grant of a Performance Cash Award, the length of any Performance Period, the Performance Goals to be achieved
during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section 162(m) of the Code, the
Board), in its sole discretion. The Board may specify the form of payment of Performance Cash Awards, which may be cash or other property, or may provide for a Participant to have the option for his or her Performance Cash Award, or such portion
thereof as the Board may specify, to be paid in whole or in part in cash or other property. 

(iii)        Board Discretion.    The Board retains the
discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a Performance Period. Partial achievement of the
specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Stock Award Agreement or the written terms of a Performance Cash Award. 

(iv)        Section 162(m) Compliance.    Unless otherwise
permitted in compliance with the requirements of Section 162(m) of the Code with respect to an Award intended to qualify as “performance-based compensation” thereunder, the Committee will establish the Performance Goals applicable to,
and the formula for calculating the amount payable under, the Award no later than the earlier of (a) the date 90 days after the commencement of the applicable Performance Period, and (b) the date on which 25% of the Performance Period has
elapsed, and in any event at a time when the achievement of the applicable Performance Goals remains substantially uncertain. Prior to the payment of any compensation under an Award intended to qualify as “performance-based compensation”
under Section 162(m) of the Code, the Committee will certify the extent to which any Performance Goals and any other material terms under such Award have been satisfied (other than in cases where such Performance Goals relate solely to the
increase in the value of the Common Stock). Notwithstanding satisfaction of, or completion of any Performance Goals, the number of shares of Common Stock, Options, cash or other benefits granted, issued, retainable and/or vested under an Award on
account of satisfaction of such Performance Goals may be reduced by the Committee on the basis of such further considerations as the Committee, in its sole discretion, will determine. 

(d)        Other Stock Awards.    Other forms of Stock
Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value of the
Common Stock at the time of grant) may be granted either alone or in addition to Stock Awards provided for under Section 5 and the preceding provisions of this Section 6. Subject to the provisions of the Plan, the Board will have sole and
complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and
all other terms and conditions of such Other Stock Awards. 

  
 13. 

	7.	 COVENANTS OF THE COMPANY. 

(a)        Availability of Shares.    The Company will keep
available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Awards. 

(b)        Securities Law Compliance.    The Company will
seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; provided,
however, that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts and at a reasonable
cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any
liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock
pursuant to the Award if such grant or issuance would be in violation of any applicable securities law. 

(c)        No Obligation to Notify or Minimize
Taxes.    The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to warn or
otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such
Award. 
  

	8.	 MISCELLANEOUS. 

(a)        Use of Proceeds from Sales of Common
Stock.    Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company. 

(b)        Corporate Action Constituting Grant of
Awards.    Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the
instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action
constituting the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award
Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents. 

(c)        Stockholder Rights.    No Participant will be
deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares
of Common Stock under, the Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to such Award has been entered into the books and records of the Company. 

  
 14. 

 (d)        No Employment or Other
Service Rights.    Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve
the Company or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause,
(ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable
provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be. 

(e)        Change in Time Commitment.    In the event a
Participant’s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a
change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding
reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction,
extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended. 

(f)        Incentive Stock Option Limitations.    To the
extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the
Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order
in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). 

(g)        Investment Assurances.    The Company may
require a Participant, as a condition of exercising or acquiring Common Stock under any Award, (i) to give written assurances satisfactory to the Company as to the Participant’s knowledge and experience in financial and business matters
and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that such Participant is capable of evaluating, alone or together with the purchaser
representative, the merits and risks of exercising the Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant’s own account and
not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or

  
 15. 

 
acquisition of Common Stock under the Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a
determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued
under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock. 

(h)        Withholding Obligations.    Unless prohibited by
the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the
Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; provided, however, that no shares of Common Stock
are withheld with a value exceeding the minimum amount of tax required to be withheld by law (or such lesser amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes);
(iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Award Agreement. 

(i)        Electronic Delivery.    Any reference herein to
a “written” agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company’s intranet (or other shared electronic
medium controlled by the Company to which the Participant has access). 

(j)        Deferrals.    To the extent permitted by
applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and
procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a
Participant is still an employee or otherwise providing services to the Company. The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments,
following the Participant’s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law. 

(k)        Compliance with Section 409A of the
Code.    Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt
from Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A of the
Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for
compliance, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and 

  
 16. 

 
unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes “deferred
compensation” under Section 409A of the Code is a “specified employee” for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a “separation from service” (as
defined in Section 409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant’s “separation from service” (as defined in
Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant’s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the
Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule. 

(l)        Clawback/Recovery.    All Awards granted under
the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are
listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board
determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of an event constituting Cause. No recovery of
compensation under such a clawback policy will be an event giving rise to a right to resign for “good reason” or “constructive termination” (or similar term) under any agreement with the Company. 

 

	9.	 ADJUSTMENTS UPON CHANGES IN COMMON STOCK;
OTHER CORPORATE EVENTS. 

(a)        Capitalization Adjustments.    In the event of a
Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities
that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(c), (iii) the class(es) and maximum number of securities that may be awarded to any person pursuant to Sections 3(d), and (iv) the class(es)
and number of securities and price per share of stock subject to outstanding Stock Awards. The Board will make such adjustments, and its determination will be final, binding and conclusive. 

(b)        Dissolution or Liquidation.    Except as
otherwise provided in the Stock Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a
forfeiture condition or the Company’s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company’s repurchase rights or subject to a
forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service; provided, however, that the Board may, in its sole discretion, cause some or
all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent
on its completion. 

  
 17. 

 (c)        Corporate
Transaction.    The following provisions shall apply to Stock Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the
Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of a Stock Award. In the event of a Corporate Transaction, then, notwithstanding any other provision of the Plan, the Board shall
take one or more of the following actions with respect to Stock Awards, contingent upon the closing or completion of the Corporate Transaction: 

(i)      arrange for the surviving corporation or acquiring corporation (or the
surviving or acquiring corporation’s parent company) to assume or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an award to acquire the same consideration paid to the
stockholders of the Company pursuant to the Corporate Transaction); 
 (ii)     arrange for
the assignment of any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent
company); 
 (iii)    accelerate the vesting, in whole or in part, of the Stock Award (and, if
applicable, the time at which the Stock Award may be exercised) to a date prior to the effective time of such Corporate Transaction as the Board shall determine (or, if the Board shall not determine such a date, to the date that is five days prior
to the effective date of the Corporate Transaction), with such Stock Award terminating if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction; 

(iv)    arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held
by the Company with respect to the Stock Award; 
 (v)     cancel or arrange for the
cancellation of the Stock Award, to the extent not vested or not exercised prior to the effective time of the Corporate Transaction, in exchange for such cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and

 (vi)    make a payment, in such form as may be determined by the Board equal to the excess,
if any, of (A) the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Corporate Transaction, over (B) any exercise price payable by such holder in
connection with such exercise. 
 The Board need not take the same action or actions with respect to all Stock Awards or
portions thereof or with respect to all Participants. The Board may take different actions with respect to the vested and unvested portions of a Stock Award. 

(d)        Change in Control.    A Stock Award may be
subject to additional acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any
Affiliate and the Participant, but in the absence of such provision, no such acceleration will occur. 

  
 18. 

	10.	 PLAN TERM; EARLIER TERMINATION OR SUSPENSION
OF THE PLAN. 

 The Board may suspend or terminate the
Plan at any time. No Incentive Stock Options may be granted after the tenth anniversary of the earlier of (i) the date the Plan is adopted by the Board (the “Adoption Date”), or (ii) the date the Plan is approved by
the stockholders of the Company. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. 
  

	11.	 EXISTENCE OF THE PLAN; TIMING OF FIRST
GRANT OR EXERCISE. 

 The Plan will come into existence
on the Adoption Date; provided, however, that no Award may be granted prior to the IPO Date. In addition, no Stock Award will be exercised (or, in the case of a Restricted Stock Award, Restricted Stock Unit Award, Performance Stock Award, or
Other Stock Award, no Stock Award will be granted) and no Performance Cash Award will be settled unless and until the Plan has been approved by the stockholders of the Company, which approval will be within 12 months after the date the Plan is
adopted by the Board. 
  

	12.	 CHOICE OF LAW. 

The law of the State of Arizona will govern all questions concerning the construction, validity and interpretation of this
Plan, without regard to that state’s conflict of laws rules. 

13.        DEFINITIONS.    As used in the Plan, the
following definitions will apply to the capitalized terms indicated below: 

(a)        “Affiliate” means, at the time of
determination, any “parent” or “subsidiary” of the Company as such terms are defined in Rule 405 of the Securities Act. The Board will have the authority to determine the time or times at which “parent” or
“subsidiary” status is determined within the foregoing definition. 
 (b)
        “Award” means a Stock Award or a Performance Cash Award. 

(c)        “Award Agreement” means a written agreement
between the Company and a Participant evidencing the terms and conditions of an Award. 

(d)        “Board” means the Board of Directors of the
Company. 
 (e)        “Capital Stock” means each and
every class of common stock of the Company, regardless of the number of votes per share. 

(f)        “Capitalization Adjustment” means any change
that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Adoption Date without the receipt of consideration by the Company through merger, consolidation,
reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in
corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial 

  
 19. 

 
Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will
not be treated as a Capitalization Adjustment. 

(g)        “Cause” shall have the meaning ascribed to
such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i) such
Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) such Participant’s attempted commission of, or participation in, a fraud
or act of dishonesty against the Company; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant and the Company or of any statutory duty owed to the Company; (iv) such
Participant’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) such Participant’s gross misconduct. The determination that a termination of the Participant’s Continuous
Service is either for Cause or without Cause shall be made by the Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding
Awards held by such Participant shall have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose. 

(h)        “Change in Control” means the occurrence, in
a single transaction or in a series of related transactions, of any one or more of the following events: 

(i)        any Exchange Act Person becomes the Owner, directly or indirectly,
of securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in
Control will not be deemed to occur (A) on account of the acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other
Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, (C) on account of
the acquisition of securities of the Company by any individual who is, on the IPO Date, either an executive officer or a Director (either, an “IPO Investor”) and/or any entity in which an IPO Investor has a direct or indirect
interest (whether in the form of voting rights or participation in profits or capital contributions) of more than 50% (collectively, the “IPO Entities”) or on account of the IPO Entities continuing to hold shares that come to
represent more than 50% of the combined voting power of the Company’s then outstanding securities as a result of the conversion of any class of the Company’s securities into another class of the Company’s securities having a different
number of votes per share pursuant to the conversion provisions set forth in the Company’s Amended and Restated Certificate of Incorporation; or (D) solely because the level of Ownership held by any Exchange Act Person (the
“Subject Person”) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares
outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any
additional voting securities that, assuming the repurchase or 

  
 20. 

 
other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in
Control will be deemed to occur; 
 (ii)        there is consummated a
merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do
not Own, directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50%
of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the
Company immediately prior to such transaction; provided, however, that a merger, consolidation or similar transaction will not constitute a Change in Control under this prong of the definition if the outstanding voting securities representing
more than 50% of the combined voting power of the surviving Entity or its parent are owned by the IPO Entities; 

(iii)        there is consummated a sale, lease, exclusive license or other
disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries
to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company
immediately prior to such sale, lease, license or other disposition; provided, however, that a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries will
not constitute a Change in Control under this prong of the definition if the outstanding voting securities representing more than 50% of the combined voting power of the acquiring Entity or its parent are owned by the IPO Entities; or 

(iv)        the stockholders of the Company approve or the Board approves a
plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company will otherwise occur, except for a liquidation into a parent corporation. 

Notwithstanding the foregoing definition or any other provision of the Plan, the term Change in Control will not include a
sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company and the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any
Affiliate and the Participant will supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual
written agreement, the foregoing definition will apply. 

(i)        “Code” means the Internal Revenue Code of
1986, as amended, including any applicable regulations and guidance thereunder. 

  
 21. 

(j)        “Committee” means a committee of one or more
Directors to whom authority has been delegated by the Board in accordance with Section 2(c). 

(k)        “Common Stock” means, as of the IPO Date,
the common stock of the Company, having one vote per share. 

(l)        “Company” means HTG Molecular Diagnostics,
Inc., a Delaware corporation. 

(m)        “Consultant” means any person, including an
advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such
services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a “Consultant” for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant
under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company’s securities to such person. 

(n)        “Continuous Service” means that the
Participant’s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an
Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant’s service with the Company or an Affiliate, will not terminate a
Participant’s Continuous Service; provided, however, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant’s
Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may
determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or
(ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the
Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. 

(o)        “Corporate Transaction” means the
consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: 

(i)        a sale or other disposition of all or substantially all, as
determined by the Board, in its sole discretion, of the consolidated assets of the Company and its Subsidiaries; 

(ii)       a sale or other disposition of at least 90% of the outstanding
securities of the Company; 
 (iii)      a merger, consolidation or similar
transaction following which the Company is not the surviving corporation; or 

  
 22. 

 (iv)        a merger,
consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of
the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise. 

(p)        “Covered Employee” will have the meaning
provided in Section 162(m)(3) of the Code. 

(q)        “Director” means a member of the Board. 

(r)        “Disability” means, with respect to a
Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last
for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.

 (s)        “Employee” means any person employed by
the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for purposes of the Plan. 

(t)        “Entity” means a corporation, partnership,
limited liability company or other entity. 
 (u)        “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 

(v)        “Exchange Act Person” means any natural
person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary of the Company, (ii) any employee
benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding
securities pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or
(v) any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the IPO Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50%
of the combined voting power of the Company’s then outstanding securities. 

(w)        “Fair Market Value” means, as of any date,
the value of the Common Stock determined as follows: 
 (i)        If the
Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on
such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable. 

  
 23. 

 (ii)        Unless otherwise
provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists. 

(iii)      In the absence of such markets for the Common Stock, the Fair Market Value
will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code. 

(x)        “Incentive Stock
Option” means an option granted pursuant to Section 5 of the Plan that is intended to be, and qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code. 

(y)        “IPO Date” means the date of the
underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering. 

(z)        “Non-Employee Director” means a Director who
either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than
as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (“Regulation S-K”)), does not possess an interest in any
other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is
otherwise considered a “non-employee director” for purposes of Rule 16b-3. 

(aa)       “Nonstatutory Stock Option” means any Option
granted pursuant to Section 5 of the Plan that does not qualify as an Incentive Stock Option. 

(bb)       “Officer” means a person who is an officer of the
Company within the meaning of Section 16 of the Exchange Act. 

(cc)       “Option” means an Incentive Stock Option or a
Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan. 

(dd)       “Option Agreement” means a written agreement
between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan. 

(ee)       “Optionholder” means a person to whom an Option
is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option. 

(ff)       “Other Stock Award” means an award based in whole
or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(d). 

  
 24. 

 (gg)       “Other Stock
Award Agreement” means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be subject to the terms and
conditions of the Plan. 
 (hh)       “Outside Director”
means a Director who either (i) is not a current employee of the Company or an “affiliated corporation” (within the meaning of Treasury Regulations promulgated under Section 162(m) of the Code), is not a former employee of the
Company or an “affiliated corporation” who receives compensation for prior services (other than benefits under a tax-qualified retirement plan) during the taxable year, has not been an officer of the Company or an “affiliated
corporation,” and does not receive remuneration from the Company or an “affiliated corporation,” either directly or indirectly, in any capacity other than as a Director, or (ii) is otherwise considered an “outside
director” for purposes of Section 162(m) of the Code. 

(ii)       “Own,” “Owned,”
“Owner,” “Ownership” means a person or Entity will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if
such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. 

(jj)       “Participant” means a person to whom an Award is
granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award. 

(kk)       “Performance Cash Award” means an award of cash
granted pursuant to the terms and conditions of Section 6(c)(ii). 

(ll)       “Performance Criteria” means the one or more
criteria that the Board will select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the
following as determined by the Board: (i) earnings (including earnings per share and net earnings); (ii) earnings before interest, taxes and depreciation; (iii) earnings before interest, taxes, depreciation and amortization;
(iv) earnings before interest, taxes, depreciation, amortization and legal settlements; (v) earnings before interest, taxes, depreciation, amortization, legal settlements and other income (expense); (vi) earnings before interest,
taxes, depreciation, amortization, legal settlements, other income (expense) and stock-based compensation; (vii) earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense), stock-based compensation
and changes in deferred revenue; (viii) earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense), stock-based compensation, other non-cash expenses and changes in deferred revenue; (ix) total
stockholder return; (x) return on equity or average stockholder’s equity; (xi) return on assets, investment, or capital employed; (xii) stock price; (xiii) margin (including gross margin); (xiv) income (before or after
taxes); (xv) operating income; (xvi) operating income after taxes; (xvii) pre-tax profit; (xviii) operating cash flow; (xix) sales or revenue targets; (xx) increases in revenue or product revenue; (xxi) expenses
and cost reduction goals; (xxii) improvement in or attainment of working capital levels; (xxiii) economic value added (or an equivalent metric); (xxiv) market share; (xxv) cash flow; (xxvi) cash flow per share;
(xxvii) cash balance; (xxviii) cash burn; (xxix) cash collections; (xxx) share price performance; (xxxi) debt reduction; (xxxii) 

  
 25. 

 
implementation or completion of projects or processes (including, without limitation, clinical trial initiation, clinical trial enrollment and dates, clinical trial results, regulatory filing
submissions, regulatory filing acceptances, regulatory or advisory committee interactions, regulatory approvals, and product supply); (xxxiii) stockholders’ equity; (xxxiv) capital expenditures; (xxxv) debt levels;
(xxxvi) operating profit or net operating profit; (xxxvii) workforce diversity; (xxxviii) growth of net income or operating income; (xxxix) billings; (xl) bookings; (xli) employee retention; (xlii) initiation of
studies by specific dates; (xliii) budget management; (xliv) submission to, or approval by, a regulatory body (including, but not limited to the U.S. Food and Drug Administration) of an applicable filing or a product;
(xlv) regulatory milestones; (xlvi) progress of internal research or development programs; (xlvii) acquisition of new customers; (xlviii) customer retention and/or repeat order rate; (xlix) improvements in sample and test
processing times; (l) progress of partnered programs; (li) partner satisfaction; (lii) timely completion of clinical trials; (liii) submission of 510(k)s or pre-market approvals and other regulatory achievements;
(liv) milestones related to samples received and/or tests or panels run; (lv) expansion of sales in additional geographies or markets; (lvi) research progress, including the development of programs; (lvii) strategic partnerships
or transactions (including in-licensing and out-licensing of intellectual property); and (lviii) and to the extent that an Award is not intended to comply with Section 162(m) of the Code, other measures of performance selected by the
Board. 
 (mm)  “Performance Goals” means, for a Performance Period, the one or
more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and
in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board (i) in the Award Agreement at the time the Award is granted
or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a
Performance Period as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects; (3) to exclude the effects of changes to generally accepted accounting principles; (4) to
exclude the effects of any statutory adjustments to corporate tax rates; (5) to exclude the effects of any “extraordinary items” as determined under generally accepted accounting principles; (6) to exclude the dilutive effects of
acquisitions or joint ventures; (7) to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; (8) to exclude the effect of
any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar
corporate change, or any distributions to common stockholders other than regular cash dividends; (9) to exclude the effects of stock based compensation and the award of bonuses under the Company’s bonus plans; (10) to exclude costs
incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; (11) to exclude the goodwill and intangible asset impairment charges that are required to be
recorded under generally accepted accounting principles; (12) to exclude the effect of any other unusual, non-recurring gain or loss or other extraordinary item; and (13) to exclude the effects of the timing of acceptance for review and/or
approval of submissions to the U.S. Food and Drug Administration or any other regulatory body. 

  
 26. 

 
In addition, the Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the
Performance Criteria it selects to use for such Performance Period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Stock Award Agreement or the
written terms of a Performance Cash Award. 
 (nn)      “Performance
Period” means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant’s right to and the payment of a Stock Award or a
Performance Cash Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board. 

(oo)      “Performance Stock Award” means a Stock Award granted
under the terms and conditions of Section 6(c)(i). 

(pp)      “Plan” means this HTG Molecular Diagnostics, Inc. 2014
Equity Incentive Plan. 
 (qq)      “Restricted Stock Award”
means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a). 

(rr)      “Restricted Stock Award Agreement” means a written
agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan. 

(ss)      “Restricted Stock Unit Award” means a right to receive
shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b). 

(tt)      “Restricted Stock Unit Award Agreement” means a written
agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the
Plan. 
 (uu)      “Rule 16b-3” means Rule 16b-3 promulgated
under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time. 

(vv)      “Securities Act” means the Securities Act of 1933, as
amended. 
 (ww)      “Stock Appreciation Right” or
“SAR” means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5. 

(xx)      “Stock Appreciation Right Agreement” means a written
agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan. 

  
 27. 

 (yy)      “Stock
Award” means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right, a Performance
Stock Award or any Other Stock Award. 
 (zz)      “Stock Award
Agreement” means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan. 

(aaa)      “Subsidiary” means, with respect to the Company,
(i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or
classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in
which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%. 

(bbb)      “Ten Percent Stockholder” means a person who Owns (or
is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. 

  
 28. 

 HTG MOLECULAR DIAGNOSTICS, INC. 

2014 EQUITY INCENTIVE PLAN 

OPTION AGREEMENT 

(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK
OPTION) 
 Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this
Option Agreement, HTG Molecular Diagnostics, Inc. (the “Company”) has granted you an option under its 2014 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s
Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is
any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions
as in the Plan. 
 The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as
follows: 
 1.        VESTING.    Subject
to the provisions contained herein [and the potential vesting acceleration provisions set forth in Section 11 herein], your option will vest as provided in your Grant Notice. Vesting will cease upon the termination of your Continuous Service.

 2.        NUMBER OF SHARES
AND EXERCISE PRICE.    The number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice will be adjusted for Capitalization
Adjustments. 
 3.        EXERCISE RESTRICTION
FOR NON-EXEMPT EMPLOYEES.    If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a
“Non-Exempt Employee”), and except as otherwise provided in the Plan, you may not exercise your option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant, even if you
have already been an employee for more than six (6) months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such six (6) month anniversary in the case of
(i) your death or disability, (ii) a Corporate Transaction in which your option is not assumed, continued or substituted, (iii) a Change in Control or (iv) your termination of Continuous Service on your “retirement” (as
defined in the Company’s benefit plans). 

4.        EXERCISE PRIOR TO
VESTING (“EARLY EXERCISE”).    If permitted in your Grant Notice (i.e., the “Exercise Schedule” indicates “Early Exercise Permitted”) and
subject to the provisions of your option, you may elect at any time that is both (i) during the period of your Continuous Service and (ii) during the term of your option, to exercise all or part of your option, including the unvested
portion of your option; provided, however, that: 
 a.        a
partial exercise of your option will be deemed to cover first vested shares of Common Stock and then the earliest vesting installment of unvested shares of Common Stock; 

  
 29. 

 b.        any shares of Common
Stock so purchased from installments that have not vested as of the date of exercise will be subject to the purchase option in favor of the Company as described in the Company’s form of Early Exercise Stock Purchase Agreement; 

c.        you will enter into the Company’s form of Early Exercise Stock
Purchase Agreement with a vesting schedule that will result in the same vesting as if no early exercise had occurred; and 

d.        if your option is an Incentive Stock Option, then, to the extent
that the aggregate Fair Market Value (determined at the Date of Grant) of the shares of Common Stock with respect to which your option plus all other Incentive Stock Options you hold are exercisable for the first time by you during any calendar year
(under all plans of the Company and its Affiliates) exceeds one hundred thousand dollars ($100,000), your option(s) or portions thereof that exceed such limit (according to the order in which they were granted) will be treated as Nonstatutory Stock
Options. 
 5.        METHOD OF
PAYMENT.    You must pay the full amount of the exercise price for the shares you wish to exercise. You may pay the exercise price in cash or by check, bank draft or money order payable to the Company or in any
other manner permitted by your Grant Notice, which may include one or more of the following: 

a.        Provided that at the time of exercise the Common Stock is publicly
traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable
instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise”, “same day sale”, or “sell to cover”. 

b.        Provided that at the time of exercise the Common Stock is publicly
traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on
the date of exercise. “Delivery” for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form
approved by the Company. You may not exercise your option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company’s stock. 

c.        If this option is a Nonstatutory Stock Option, subject to the
consent of the Company at the time of exercise, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a
Fair Market Value that does not exceed the aggregate exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Shares of Common Stock
will no longer be outstanding under your option and will not be exercisable thereafter if those shares (i) are used to pay the exercise price pursuant to the “net exercise,” (ii) are delivered to you as a result of such exercise,
and (iii) are withheld to satisfy your tax withholding obligations. 

  
 30. 

 6.        WHOLE
SHARES.    You may exercise your option only for whole shares of Common Stock. 

7.        SECURITIES LAW
COMPLIANCE.    In no event may you exercise your option unless the shares of Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined
that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you
may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if
applicable). 
 8.        TERM.    You may
not exercise your option before the Date of Grant or after the expiration of the option’s term. The term of your option expires, subject to the provisions of Section 5(h) of the Plan, upon the earliest of the following: 

a.        immediately upon the termination of your Continuous Service for
Cause; 
 b.        three (3) months after the termination of your
Continuous Service for any reason other than Cause, your Disability or your death (except as otherwise provided in Section 8(d) below); provided, however, that if during any part of such three (3) month period your option is not
exercisable solely because of the condition set forth in the section above relating to “Securities Law Compliance,” your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate
period of three (3) months after the termination of your Continuous Service; provided further, if during any part of such three (3) month period, the sale of any Common Stock received upon exercise of your option would violate the
Company’s insider trading policy, then your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service
during which the sale of the Common Stock received upon exercise of your option would not be in violation of the Company’s insider trading policy. Notwithstanding the foregoing, if (i) you are a Non-Exempt Employee, (ii) your
Continuous Service terminates within six (6) months after the Date of Grant, and (iii) you have vested in a portion of your option at the time of your termination of Continuous Service, your option will not expire until the earlier of
(x) the later of (A) the date that is seven (7) months after the Date of Grant, and (B) the date that is three (3) months after the termination of your Continuous Service, and (y) the Expiration Date; 

c.        twelve (12) months after the termination of your Continuous
Service due to your Disability (except as otherwise provided in Section 8(d)) below; 

d.        eighteen (18) months after your death if you die either during
your Continuous Service or within three (3) months after your Continuous Service terminates for any reason other than Cause; 

e.        the Expiration Date indicated in your Grant Notice; or 

  
 31. 

 f.        the day before the
tenth (10th) anniversary of the Date of Grant. 
 If your option is an Incentive Stock Option, note that to obtain the
federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the Date of Grant and ending on the day three (3) months before the date of your option’s exercise, you must be an
employee of the Company or an Affiliate, except in the event of your death or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will
necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three
(3) months after the date your employment with the Company or an Affiliate terminates. 
  

	 	9.	 EXERCISE. 

a.         You may exercise the vested portion of your option (and the
unvested portion of your option if your Grant Notice so permits) during its term by (i) delivering a Notice of Exercise (in a form designated by the Company) or completing such other documents and/or procedures designated by the Company for
exercise and (ii) paying the exercise price and any applicable withholding taxes to the Company’s Secretary, stock plan administrator, or such other person as the Company may designate, together with such additional documents as the
Company may then require. 
 b.        By exercising your option you agree
that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise
of your option, (ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise. 

c.        If your option is an Incentive Stock Option, by exercising your
option you agree that you will notify the Company in writing within fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the
Date of Grant or within one (1) year after such shares of Common Stock are transferred upon exercise of your option. 

d.        By accepting your option you agree that you will not sell, dispose
of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any shares of Common Stock or other securities of the Company held by you, for a
period of one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with
FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rules or regulation (the “Lock-Up Period”); provided, however, that nothing contained in this section will prevent the exercise of a repurchase
option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing

  
 32. 

 
or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock
until the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section 9(d). The underwriters of the Company’s stock are intended third
party beneficiaries of this Section 9(d) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

10.       TRANSFERABILITY.    Except as otherwise
provided in this Section 10, your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you. 

a.        Certain Trusts.    Upon receiving written
permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is
held in the trust. You and the trustee must enter into transfer and other agreements required by the Company. 

b.        Domestic Relations Orders.    Upon receiving
written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic
relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are encouraged
to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order
or marital settlement agreement. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. 

c.        Beneficiary Designation.    Upon receiving
written permission from the Board or its duly authorized designee, you may, by delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party
who, on your death, will thereafter be entitled to exercise this option and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be
entitled to exercise this option and receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise. 

[11. CHANGE IN CONTROL. 

[(a)        If a Change in Control occurs and immediately prior to or within
twelve (12) months after, the effective time of such Change in Control your Continuous Service terminates due to an involuntary termination (not including death or Disability) without Cause or due to a voluntary termination with Good Reason,
then, as of the date of termination of Continuous Service, the vesting and exercisability of your option will be accelerated in full. 

  
 33. 

 (b)        “Good
Reason” means that one or more of the following are undertaken by the Company (or successor to the Company, if applicable) without your express written consent: (i) a material reduction in your annual base salary; provided, however,
that Good Reason will not be deemed to have occurred in the event of a reduction in your annual base salary that is pursuant to a salary reduction program affecting substantially all of the employees of the Company and that does not adversely affect
you to a greater extent than other similarly situated employees; (ii) a material reduction in your authority, duties or responsibilities; (iii) any failure by the Company to continue in effect any material benefit plan or program,
including incentive plans or plans with respect to the receipt of securities of the Company, in which you were participating immediately prior to the effective date of the Change in Control (hereinafter referred to as “Benefit
Plans”), or the taking of any action by the Company that would adversely affect your participation in or reduce your benefits under the Benefit Plans or deprive you of any fringe benefit that you enjoyed immediately prior to the
effective date of the Change in Control; provided, however, that Good Reason will not be deemed to have occurred if the Company provides for your participation in benefit plans and programs that, taken as a whole, are comparable to the Benefit
Plans; (iv) a relocation of your principal place of employment with the Company (or successor to the Company, if applicable) to a place that increases your one-way commute by more than fifty (50) miles as compared to your then-current
principal place of employment immediately prior to such relocation, except for required travel by you on the Company’s business to an extent substantially consistent with your business travel obligations prior to the effective date of the
Change in Control; or (v) a material breach by the Company of any provision of the Plan or the Option Agreement or any other material agreement between you and the Company concerning the terms and conditions of your employment or service with
the Company.] 
 (a)        The vesting and exercisability of your option
will be accelerated in full upon a Change in Control. 
 (b)        If any
payment or benefit you would receive from the Company or otherwise in connection with a Change in Control or other similar transaction (a “280G Payment”) would (i) constitute a “parachute payment” within the
meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then any such 280G Payment (a
“Payment”) shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being
subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and
local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment
may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding 

  
 34. 

 
sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the “Reduction Method”) that
results in the greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the “Pro Rata Reduction Method”). 

Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the
Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be,
shall be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as
determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and
(C) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A of the Code shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of
Section 409A of the Code. 
 Unless you and the Company agree on an alternative accounting firm, the accounting firm
engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the change of control transaction triggering the Payment shall perform the foregoing calculations. If the accounting firm so engaged by the
Company is serving as accountant or auditor for the individual, entity or group effecting the change of control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company
shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to
provide its calculations, together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your right to a 280G Payment becomes reasonably likely to occur (if requested at that
time by you or the Company) or such other time as requested by you or the Company. 
 If you receive a Payment for which
the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section 11(b) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly
return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section 11(b) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of
doubt, if the Reduced Amount was determined pursuant to clause (y) in the first paragraph of this Section 11(b), you shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.] 

  
 35. 

 11.        OPTION
NOT A SERVICE CONTRACT.    Your option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any
obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective
stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate. 

12.        WITHHOLDING OBLIGATIONS. 

a.        At the time you exercise your option, in whole or in part, and at
any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “same day sale” pursuant to a
program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate,
if any, which arise in connection with the exercise of your option. 

b.        If this option is a Nonstatutory Stock Option, then upon your
request and subject to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a
number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid
classification of your option as a liability for financial accounting purposes). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the
preceding sentence shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination
is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares
of Common Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole
responsibility. 
 c.        You may not exercise your option unless the tax
withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for
such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied. 

13.        TAX CONSEQUENCES. You hereby agree
that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees
or Affiliates related to tax liabilities arising from your option or your other 

  
 36. 

 
compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to
the “fair market value” per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option. 

14.        NOTICES.    Any notices provided
for in your option or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United
States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to
request your consent to participate in the Plan by electronic means. By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and
maintained by the Company or another third party designated by the Company. 

15.        GOVERNING PLAN
DOCUMENT.    Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and
regulations, which may from time to time be promulgated and adopted pursuant to the Plan. If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. In addition, your option (and
any compensation paid or shares issued under your option) is subject to recoupment in accordance with The Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the
Company and any compensation recovery policy otherwise required by applicable law. 

16.        OTHER
DOCUMENTS.    You hereby acknowledge receipt of and the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus.
In addition, you acknowledge receipt of the Company’s policy permitting certain individuals to sell shares only during certain “window” periods and the Company’s insider trading policy, in effect from time to time. 

17.        EFFECT ON OTHER
EMPLOYEE BENEFIT PLANS.    The value of this option will not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any
employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company’s or any Affiliate’s employee
benefit plans. 
 18.        VOTING
RIGHTS.    You will not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this option until such shares are issued to you. Upon such issuance,
you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this option, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship
between you and the Company or any other person. 

19.        SEVERABILITY.    If all or any
part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity 

  
 37. 

 
will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section) so declared to be
unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. 

20.        MISCELLANEOUS. 

a.        The rights and obligations of the Company under your option will be
transferable to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company’s successors and assigns. 

b.        You agree upon request to execute any further documents or
instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option. 

c.        You acknowledge and agree that you have reviewed your option in its
entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option. 

d.        This Option Agreement will be subject to all applicable laws, rules,
and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required. 

e.        All obligations of the Company under the Plan and this Option
Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the
Company. 
 *        *        * 

This Option Agreement will be deemed to be signed by you upon the signing by you of the Stock Option Grant Notice to which it
is attached. 

  
 38. 

 NOTICE OF EXERCISE 

HTG Molecular Diagnostics, Inc. 
 3430 E.
Global Loop 
 Tucson, AZ 85706
                                         
                                         
                  Date of Exercise:                 

This constitutes notice to HTG Molecular Diagnostics, Inc. (the “Company”) under my stock option that
I elect to purchase the below number of shares of Common Stock of the Company (the “Shares”) for the price set forth below. 
  

					
	 Type of option (check one):
		 Incentive  ̈
		 Nonstatutory  ̈

			
	 Stock option dated:
				
			
	Number of Shares as to which option is exercised:				
			
	Certificates to be issued in name of:				
			
	Total exercise price:		
$                            

		
$                            

			
	Cash payment delivered herewith:		
$                            

		
$                            

			
	[Value of             Shares delivered herewith1:		
$                            

		
$                            
]

			
	[Value of             Shares pursuant to net exercise2:		
$                            

		
$                            
]

			
	[Regulation T Program (cashless exercise3):		
$                            

		
$                            
]

  
  

1        Shares must meet the public trading
requirements set forth in the option. Shares must be valued in accordance with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or
accompanied by an executed assignment separate from certificate. 

2        The option must be a Nonstatutory Stock
Option, and HTG Molecular Diagnostics, Inc. must have established net exercise procedures at the time of exercise, in order to utilize this payment method. 

3        Shares must meet the public trading
requirements set forth in the option. 

  
 39. 

 By this exercise, I agree (i) to provide such additional documents as you
may require pursuant to the terms of the HTG Molecular Diagnostics, Inc. 2014 Equity Incentive Plan, (ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise
of this option, and (iii) if this exercise relates to an incentive stock option, to notify you in writing within fifteen (15) days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs
within two (2) years after the date of grant of this option or within one (1) year after such Shares are issued upon exercise of this option. 
  

	
	 Very truly yours,

	
	  

	

  
 40. 

 HTG MOLECULAR DIAGNOSTICS, INC.

 STOCK OPTION GRANT NOTICE 

(2014 EQUITY INCENTIVE PLAN) 

HTG Molecular Diagnostics, Inc. (the “Company”), pursuant to its 2014 Equity Incentive Plan (the
“Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this notice, in
the Option Agreement, the Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement will have the same
definitions as in the Plan or the Option Agreement. If there is any conflict between the terms in this notice and the Plan, the terms of the Plan will control. 
  

			
	 Optionholder:
		  

	 Date of Grant:
		  

	 Vesting Commencement Date:
		  

	 Number of Shares Subject to Option:
		  

	 Exercise Price (Per Share):
		  

	 Total Exercise Price:
		  

	 Expiration Date:
		  

  

					
			
	 Type of Grant:
		  ̈ Incentive Stock Option2
		  ̈ Nonstatutory Stock Option

			
	 Exercise Schedule:
		 x Same as Vesting Schedule
		  ̈ Early Exercise Permitted

		
	 Vesting Schedule:
		 [1/4th of the shares vest on the one year anniversary of the Vesting Commencement
Date; the balance of the shares vest in a series of twelve (12) successive equal quarterly installments on the last day of each calendar quarter, commencing with the last day of the calendar quarter first occurring after the one year
anniversary of the Vesting Commencement Date, subject to the Optionholder’s Continuous Service through each such vesting date.]3

		
			 [The shares vest in a series of sixteen (16) successive equal quarterly installments on the last day of each calendar quarter,
commencing with the last day of the calendar quarter first occurring after the Vesting Commencement Date, subject to the Optionholder’s Continuous Service through each such vesting
date.]4

		
			 [Initial Grant: One-third (1/3rd) of the shares vest one year after the Vesting
Commencement Date; the balance of the shares vest in a series of twenty-four (24) successive equal monthly installments on the last day of each calendar month, commencing with the last day of the calendar month first occurring after the one
year anniversary of the Vesting Commencement Date, subject to the Optionholder’s Continuous Service through each such vesting date.]

		
			 [Annual Grant: The shares vest in a series of twelve (12) successive equal monthly installments on the last day of each calendar
month, commencing with the last day of the calendar month first occurring after the Vesting Commencement Date, subject to the Optionholder’s Continuous Service through each such vesting date.]

  
  

2 If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options)
cannot be first exercisable for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option. 

3 Insert this vesting schedule for initial option grants to employees. 

4 Insert this vesting schedule for option grants other than the initial option
grant to employees. 

  
 41. 

			
	Payment:		 By one or a combination of the following items (described in the Option Agreement):

		
			 x       By cash, check, bank
draft or money order payable to the Company

			 x       Pursuant to a Regulation
T Program if the shares are publicly traded

			 x       By delivery of
already-owned shares if the shares are publicly traded

			
x       If and only
to the extent this option is a Nonstatutory Stock Option, and subject to the
 Company’sconsent
at the time of exercise, by a “net exercise” arrangement

  
 42. 

 Additional Terms/Acknowledgements: Optionholder acknowledges receipt of, and understands
and agrees to, this Stock Option Grant Notice, the Option Agreement and the Plan. Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the
Plan. Optionholder further acknowledges that as of the Date of Grant, this Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and
supersede all prior oral and written agreements, promises and/or representations on that subject with the exception of (i) options previously granted and delivered to Optionholder, (ii) any compensation recovery policy that is adopted by
the Company or is otherwise required by applicable law and (iii) any written employment or severance arrangement that would provide for vesting acceleration of this option upon the terms and conditions set forth therein. By accepting this
option, Optionholder consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. 

 

									
	HTG MOLECULAR DIAGNOSTICS, INC.	 		 	OPTIONHOLDER:
					
	By:	 	 	 		 		 	 
		 	Signature	 		 		 	Signature
					
	Title:	 	 	 		 	Date:	 	 
					
	Date:	 	 	 		 		 	

 ATTACHMENTS: Option Agreement, 2014 Equity Incentive Plan and Notice of Exercise 

  
 43. 

 ATTACHMENT I 

OPTION AGREEMENT 

  
 44. 

 ATTACHMENT II 

2014 EQUITY INCENTIVE PLAN 

  
 45. 

 ATTACHMENT III 

NOTICE OF EXERCISE 

  
 46.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]